The 87th Annual Meeting of the Japanese Society of Hematology MICEnavi

KojiKato{KatoKoji}|Wei-LiZhao{ZhaoWei-Li}|LorenzoFalchi{FalchiLorenzo}|MarkRoschewski{RoschewskiMark}____KojiIzutsu{IzutsuKoji}|LorenzoFalchi{FalchiLorenzo}________Symposium 1Emerging treatment for B cell lymphoma____Clinical trial overview of first-line treatment for DLBCL|Genetic subtype-guided immunochemotherapy in malignant lymphoma|The role of bispecific antibodies in the treatment of relapsed or refractory DLBCL|Treatment response assessment with ultrasensitive circulating tumor DNA in large B-cell lymphoma

SY1

Symposium 1
Emerging treatment for B cell lymphoma

Chair：Koji Izutsu, Chair：Lorenzo Falchi

MarkLevis{LevisMark}|CatherineC.Smith{SmithCatherineC.}____HitoshiKiyoi{KiyoiHitoshi}________Presidential SymposiumTherapeutic strategy for AML with FLT3 mutations____Management of FLT3-mutated AML|An evolving understanding of resistance to FLT3 inhibitors in AML

PSY

Presidential Symposium
Therapeutic strategy for AML with FLT3 mutations

Chair：Hitoshi Kiyoi

BelindaAvalos{AvalosBelinda}____KoichiAkashi{AkashiKoichi}________ASH Special LectureGerm line CSF3R mutations in CNL____Germ line CSF3R mutations in CNL

ASH

ASH Special Lecture
Germ line CSF3R mutations in CNL

Chair：Koichi Akashi

Speaker：Belinda Avalos

HitoshiKiyoi{KiyoiHitoshi}____TomokiNaoe{NaoeTomoki}________Presidential LectureOvercoming acute myeloid leukemia____Overcoming acute myeloid leukemia

CL

Presidential Lecture
Overcoming acute myeloid leukemia

Chair：Tomoki Naoe

Speaker：Hitoshi Kiyoi

EmilyHeikamp{HeikampEmily}|RobertBradley{BradleyRobert}|AkinoriYoda{YodaAkinori}|AyanaKon{KonAyana}____TakahiroYamauchi{YamauchiTakahiro}|BelindaAvalos{AvalosBelinda}____DaisukeMorishita{MorishitaDaisuke}|YotaroOchi{OchiYotaro}|AkioMizutani{MizutaniAkio}|HirokazuTozaki{TozakiHirokazu}|YoshihikoSatoh{SatohYoshihiko}|TakutoMori{MoriTakuto}|JuneTakeda{TakedaJune}|HidekiMakishima{MakishimaHideki}|MasahiroNakagawa{NakagawaMasahiro}|YasuhitoNannya{NannyaYasuhito}|SeishiOgawa{OgawaSeishi}____JSH-ASH Joint SymposiumRecent advances in molecular pathogenesis of acute leukemia____Menin inhibitors in acute leukemia treatment – the basic and clinical cutting edge|Mis-splicing-derived neoantigens and cognate TCRs in splicing factor mutant leukemias|Biomarkers for response to CLK inhibitor CTX-712 in myeloid neoplasms: Paving the way toward clinical application|Genetic and functional analysis of germline and somatic DDX41 variants associated with myeloid malignancies

ASHSY

JSH-ASH Joint Symposium
Recent advances in molecular pathogenesis of acute leukemia

Chair：Takahiro Yamauchi, Chair：Belinda Avalos

MotoshiIchikawa{IchikawaMotoshi}____YasushiMiyazaki{MiyazakiYasushi}________Educational Lecture 1-2-1Management of MDS according to risk classifications____Management of MDS according to risk classifications

EL1-2-1

Educational Lecture 1-2-1
Management of MDS according to risk classifications

Chair：Yasushi Miyazaki

Speaker：Motoshi Ichikawa

MarikoEguchi{EguchiMariko}____KiminoriTerui{TeruiKiminori}________Educational Lecture 1-2-2Genetic alterations in myelodysplastic neoplasms of childhood____Genetic alterations in myelodysplastic neoplasms of childhood

EL1-2-2

Educational Lecture 1-2-2
Genetic alterations in myelodysplastic neoplasms of childhood

Chair：Kiminori Terui

Speaker：Mariko Eguchi

HirokazuTanaka{TanakaHirokazu}____KeitaKirito{KiritoKeita}________Educational Lecture 1-2-3Emerging treatment approaches targeting the molecular pathogenesis of myelofibrosis____Emerging treatment approaches targeting the molecular pathogenesis of myelofibrosis

EL1-2-3

Educational Lecture 1-2-3
Emerging treatment approaches targeting the molecular pathogenesis of myelofibrosis

Chair：Keita Kirito

Speaker：Hirokazu Tanaka

SeiichiOkabe{OkabeSeiichi}____TakaakiOno{OnoTakaaki}________Educational Lecture 1-2-4Mechanisms of resistance to the allosteric BCR::ABL1 inhibitor asciminib____Mechanisms of resistance to the allosteric BCR::ABL1 inhibitor asciminib

EL1-2-4

Educational Lecture 1-2-4
Mechanisms of resistance to the allosteric BCR::ABL1 inhibitor asciminib

Chair：Takaaki Ono

Speaker：Seiichi Okabe

ChikakoTono{TonoChikako}____HidefumiHiramatsu{HiramatsuHidefumi}________Educational Lecture 1-2-5Treatment of pediatric chronic myeloid leukemia____Treatment of pediatric chronic myeloid leukemia

EL1-2-5

Educational Lecture 1-2-5
Treatment of pediatric chronic myeloid leukemia

Chair：Hidefumi Hiramatsu

Speaker：Chikako Tono

DaisukeKurotaki{KurotakiDaisuke}____TomohikoTamura{TamuraTomohiko}________Educational Lecture 1-2-6Investigation of 3D chromatin structures____Investigation of 3D chromatin structures

EL1-2-6

Educational Lecture 1-2-6
Investigation of 3D chromatin structures

Chair：Tomohiko Tamura

Speaker：Daisuke Kurotaki

IkueTai-Nagara{Tai-NagaraIkue}____NobuyukiTakakura{TakakuraNobuyuki}________Educational Lecture 1-2-7Mechanisms maintaining the homeostasis of blood and lymphatic vessels____Mechanisms maintaining the homeostasis of blood and lymphatic vessels

EL1-2-7

Educational Lecture 1-2-7
Mechanisms maintaining the homeostasis of blood and lymphatic vessels

Chair：Nobuyuki Takakura

Speaker：Ikue Tai-Nagara

AiKotani{KotaniAi}____YasuhitoNannya{NannyaYasuhito}________Educational Lecture 1-2-8New mechanisms and therapeutic targets for viral tumors____New mechanisms and therapeutic targets for viral tumors

EL1-2-8

Educational Lecture 1-2-8
New mechanisms and therapeutic targets for viral tumors

Chair：Yasuhito Nannya

Speaker：Ai Kotani

ShikikoUeno{UenoShikiko}____HideoHarigae{HarigaeHideo}________Educational Lecture 1-3-1Challenges in optimizing targeted complement inhibitor therapy for paroxysmal nocturnal hemoglobinuria in an expanding treatment landscape____Challenges in optimizing targeted complement inhibitor therapy for paroxysmal nocturnal hemoglobinuria in an expanding treatment landscape

EL1-3-1

Educational Lecture 1-3-1
Challenges in optimizing targeted complement inhibitor therapy for paroxysmal nocturnal hemoglobinuria in an expanding treatment landscape

Chair：Hideo Harigae

Speaker：Shikiko Ueno

HideyukiNakazawa{NakazawaHideyuki}____KaichiNishiwaki{NishiwakiKaichi}________Educational Lecture 1-3-2Acquired pure red cell aplasia____Acquired pure red cell aplasia

EL1-3-2

Educational Lecture 1-3-2
Acquired pure red cell aplasia

Chair：Kaichi Nishiwaki

Speaker：Hideyuki Nakazawa

YoshitakaZaimoku{ZaimokuYoshitaka}____HiroshiKawabata{KawabataHiroshi}________Educational Lecture 1-3-3HLA loss in aplastic anemia____HLA loss in aplastic anemia

EL1-3-3

Educational Lecture 1-3-3
HLA loss in aplastic anemia

Chair：Hiroshi Kawabata

Speaker：Yoshitaka Zaimoku

NaomiShimizu{ShimizuNaomi}____YoshikoTamai{TamaiYoshiko}________Educational Lecture 1-3-4Clinical significance of irregular antibodies____Clinical significance of irregular antibodies

EL1-3-4

Educational Lecture 1-3-4
Clinical significance of irregular antibodies

Chair：Yoshiko Tamai

Speaker：Naomi Shimizu

AkihisaSawada{SawadaAkihisa}____AyakoArai{AraiAyako}________Educational Lecture 1-3-5Update on allogeneic hematopoietic stem cell transplantation in chronic active Epstein-Barr virus disease____Update on allogeneic hematopoietic stem cell transplantation in chronic active Epstein-Barr virus disease

EL1-3-5

Educational Lecture 1-3-5
Update on allogeneic hematopoietic stem cell transplantation in chronic active Epstein-Barr virus disease

Chair：Ayako Arai

Speaker：Akihisa Sawada

YukiArakawa{ArakawaYuki}____ItaruKato{KatoItaru}________Educational Lecture 1-3-6Skeletal complications in pediatric and AYA patients with acute lymphoblastic leukemia____Skeletal complications in pediatric and AYA patients with acute lymphoblastic leukemia

EL1-3-6

Educational Lecture 1-3-6
Skeletal complications in pediatric and AYA patients with acute lymphoblastic leukemia

Chair：Itaru Kato

Speaker：Yuki Arakawa

NaoYoshida{YoshidaNao}____KimikazuMatsumoto{MatsumotoKimikazu}________Educational Lecture 1-3-7Aplastic anemia in children: recent advances in diagnosis and treatment____Aplastic anemia in children: recent advances in diagnosis and treatment

EL1-3-7

Educational Lecture 1-3-7
Aplastic anemia in children: recent advances in diagnosis and treatment

Chair：Kimikazu Matsumoto

Speaker：Nao Yoshida

HidekiAraoka{AraokaHideki}____MasaoHagihara{HagiharaMasao}________Educational Lecture 1-3-8Prolonged viral shedding of SARS-CoV-2 in patients with hematologic malignancies____Prolonged viral shedding of SARS-CoV-2 in patients with hematologic malignancies

EL1-3-8

Educational Lecture 1-3-8
Prolonged viral shedding of SARS-CoV-2 in patients with hematologic malignancies

Chair：Masao Hagihara

Speaker：Hideki Araoka

AyakoNakamura-Ishizu{Nakamura-IshizuAyako}|KeiyoTakubo{TakuboKeiyo}|NinaCabezas-Wallscheid{Cabezas-WallscheidNina}|YoshihiroHayashi{HayashiYoshihiro}|KeisukeIto{ItoKeisuke}____AyakoNakamura-Ishizu{Nakamura-IshizuAyako}|HideyoHirai{HiraiHideyo}________Symposium 2Energy acquisition in hematopoietic stem cells____Intracellular iron dynamics regulate hematopoietic stem cells|Metabolic rewiring of hematopoietic stem cells during the life course|Differentiation, aging and leukemia alters the metabolic profile of human bone marrow hematopoietic stem and progenitor cells|Aberrant mitochondrial dynamics in myeloid neoplasms|Mitochondrial contributions to hematopoietic homeostasis and the pathogenesis of hematological disorders

SY2

Symposium 2
Energy acquisition in hematopoietic stem cells

Chair：Ayako Nakamura-Ishizu, Chair：Hideyo Hirai

NorimitsuInoue{InoueNorimitsu}|DimitriosC.Mastellos{MastellosDimitriosC.}|ChristophSchmidt{SchmidtChristoph}|ToshiyukiMiyata{MiyataToshiyuki}____YasutakaUeda{UedaYasutaka}|NaoshiObara{ObaraNaoshi}________Symposium 3Exploring the complement system in hematology: biological insights and emerging therapeutic prospects____Hematological diseases caused by excessive complement activation|Complement biology, pathobiology and therapeutic opportunities|Selection of complement inhibitors in PNH from the perspective of complement mechanisms|Complement and coagulation in immunothrombosis

SY3

Symposium 3
Exploring the complement system in hematology: biological insights and emerging therapeutic prospects

Chair：Yasutaka Ueda, Chair：Naoshi Obara

YotaroOchi{OchiYotaro}|ShigekiHirabayashi{HirabayashiShigeki}|ShojiSaito{SaitoShoji}|ShunUkai{UkaiShun}|WataruSaika{SaikaWataru}____YoshikaneKikushige{KikushigeYoshikane}____MarkusLiew{LiewMarkus}|YasuhitoNannya{NannyaYasuhito}|SofiaBengtzen{BengtzenSofia}|SenjiKasahara{KasaharaSenji}|NobuhiroHiramoto{HiramotoNobuhiro}|NobuhiroKanemura{KanemuraNobuhiro}|NobuoSezaki{SezakiNobuo}|MakiSakurada{SakuradaMaki}|MakotoIwasaki{IwasakiMakoto}|JunyaKanda{KandaJunya}|YasunoriUeda{UedaYasunori}|SatoshiYoshihara{YoshiharaSatoshi}|YuWatanabe{WatanabeYu}|MasanoriMotomura{MotomuraMasanori}|MasahiroNakagawa{NakagawaMasahiro}|RyunosukeSaiki{SaikiRyunosuke}|HidehitoFukushima{FukushimaHidehito}|KojiOkazaki{OkazakiKoji}|AkinoriYoda{YodaAkinori}|RurikaOkuda{OkudaRurika}|ShintaroKomatsu{KomatsuShintaro}|LanyingZhao{ZhaoLanying}|YuichiShiraishi{ShiraishiYuichi}|TakayukiIshikawa{IshikawaTakayuki}|SatoruMiyano{MiyanoSatoru}|AkifumiTakaori{TakaoriAkifumi}|HiroshiSuzuki{SuzukiHiroshi}|SorenLehmann{LehmannSoren}|SeishiOgawa{OgawaSeishi}|MomokaTsuruhara{TsuruharaMomoka}|KyokoFukushi{FukushiKyoko}|ShokoTarumoto{TarumotoShoko}|MoeShinagawa{ShinagawaMoe}|YoshihiroMizuno{MizunoYoshihiro}|YuichiroSemba{SembaYuichiro}|TakuyaYamamoto{YamamotoTakuya}|KiyokoMiyata{MiyataKiyoko}|MasahitoOhue{OhueMasahito}|TaroTsujimura{TsujimuraTaro}|TakahiroMaeda{MaedaTakahiro}|AikoHasegawa{HasegawaAiko}|YuichiroIde{IdeYuichiro}|YuFurui{FuruiYu}|AkaneMiura{MiuraAkane}|TomoyaInoue{InoueTomoya}|MiyukiTanaka{TanakaMiyuki}|EriOkura{OkuraEri}|KenichiSakamoto{SakamotoKenichi}|KoichiHirabayashi{HirabayashiKoichi}|SayakaNishina{NishinaSayaka}|HitoshiSakai{SakaiHitoshi}|HideyukiNakazawa{NakazawaHideyuki}|HidekiMakishima{MakishimaHideki}|YuhoNajima{NajimaYuho}|NorikoDoki{DokiNoriko}|HarukoTashiro{TashiroHaruko}|JunichiroYuda{YudaJunichiro}|YozoNakazawa{NakazawaYozo}|YuichiIshikawa{IshikawaYuichi}|ShutoNegishi{NegishiShuto}|HarukaOkada{OkadaHaruka}|KennichiroTakeda{TakedaKennichiro}|YutaroSuzuki{SuzukiYutaro}|TakanoriNishino{NishinoTakanori}|SatoshiIwata{IwataSatoshi}|MikaTakai{TakaiMika}|YokoUshijima{UshijimaYoko}|KazuyukiShimada{ShimadaKazuyuki}|HitoshiKiyoi{KiyoiHitoshi}|KoutarouNishimura{NishimuraKoutarou}|AtsushiTanaka{TanakaAtsushi}|JuneTakeda{TakedaJune}|AyanaKon{KonAyana}|KazunariAoki{AokiKazunari}|SeigiOshima{OshimaSeigi}|ShinriOkada{OkadaShinri}|DaichiMorii{MoriiDaichi}|WeijiaZang{ZangWeijia}|TakayaYamasaki{YamasakiTakaya}|HiromiIto{ItoHiromi}|YuiKoike{KoikeYui}|HiromiYamazaki{YamazakiHiromi}|MasakiNomura{NomuraMasaki}|ManabuNakayama{NakayamaManabu}|HiromiTatsumi{TatsumiHiromi}|MasashiMatsuda{MatsudaMasashi}|KosukeYusa{YusaKosuke}|HaruhikoKoseki{KosekiHaruhiko}|MakotoMurata{MurataMakoto}|DaichiInoue{InoueDaichi}____Oral Session 1-9AAML: Basic 1____Deciphering transcription factor dysregulation across AML subtypes and differentiation hierarchies|Comprehensive functional profiling of DDX41 variants via high-throughput screening|Monocytic lineage, FLT3-ITD, and KMT2Ar in AML are associated with the CD116 overexpression|Clonal selection and macrophage remodeling after FLT3 inhibitor treatment in FLT3-ITD AML model|Unraveling clonal evolution and targeted therapeutics in SETBP1-mutated leukemia

O1-9A

Oral Session 1-9A
AML: Basic 1

Chair：Yoshikane Kikushige

SatoruTakada{TakadaSatoru}|JunichiroYuda{YudaJunichiro}|NaokoHosono{HosonoNaoko}|DaisukeKoyama{KoyamaDaisuke}|TakeshiKondo{KondoTakeshi}|HiroshiHanda{HandaHiroshi}____HisayukiYokoyama{YokoyamaHisayuki}____HiroshiKosugi{KosugiHiroshi}|JunichiroYuda{YudaJunichiro}|KohmeiKubo{KuboKohmei}|TetsuyaNishida{NishidaTetsuya}|NaokoHosono{HosonoNaoko}|KensukeUsuki{UsukiKensuke}|HiromiIwasaki{IwasakiHiromi}|NaoeGoto{GotoNaoe}|TomoakiFujisaki{FujisakiTomoaki}|NoboruAsada{AsadaNoboru}|HiroakiShimizu{ShimizuHiroaki}|TatsuroJo{JoTatsuro}|HisayukiYokoyama{YokoyamaHisayuki}|KazuoIto{ItoKazuo}|GoFujimoto{FujimotoGo}|KuretakeSoejima{SoejimaKuretake}|JinHayakawa{HayakawaJin}|YukaYasui{YasuiYuka}|DanielLopesdeMenezes{LopesdeMenezesDaniel}|ToshihiroMiyamoto{MiyamotoToshihiro}|KentaroFukushima{FukushimaKentaro}|TakahiroShima{ShimaTakahiro}|YasushiMiyazaki{MiyazakiYasushi}|TakayukiIkezoe{IkezoeTakayuki}|KoichiOnodera{OnoderaKoichi}|YoshiakiOgawa{OgawaYoshiaki}|TakanoriTeshima{TeshimaTakanori}|HirokiYamaguchi{YamaguchiHiroki}|JustinWatts{WattsJustin}|JoshuaZeidner{ZeidnerJoshua}|MarkLevis{LevisMark}|HarryErba{ErbaHarry}|CristinaPapayannidis{PapayannidisCristina}|UmaBorate{BorateUma}|PauMontesinos{MontesinosPau}|SusanaVives{VivesSusana}|EmmanuelRaffoux{RaffouxEmmanuel}|AndrewBrunner{BrunnerAndrew}|HongliangCai{CaiHongliang}|CurtisAllred{AllredCurtis}|BoXu{XuBo}|PriyaRobson{RobsonPriya}|TakahiroKuwaki{KuwakiTakahiro}|MatthewHitron{HitronMatthew}|JatinShah{ShahJatin}|HagopM.Kantarjian{KantarjianHagopM.}|NavelDaver{DaverNavel}|YusakuTomiyama{TomiyamaYusaku}|KentoIsogaya{IsogayaKento}|TakahiroYamauchi{YamauchiTakahiro}|KengoSuzuki{SuzukiKengo}|MasahikoFukatsu{FukatsuMasahiko}|YukiSato{SatoYuki}|JunNakata{NakataJun}|DaisukeMotooka{MotookaDaisuke}|YoshikiNakae{NakaeYoshiki}|ManabuKawakami{KawakamiManabu}|YutaKatayama{KatayamaYuta}|RyotaImanaka{ImanakaRyota}|JunyaKuroda{KurodaJunya}|TakuTeramoto{TeramotoTaku}|AtsushiSatake{SatakeAtsushi}|HideakiYoshimura{YoshimuraHideaki}|TakashiSonoki{SonokiTakashi}|HirokiHosoi{HosoiHiroki}|ShigekiIto{ItoShigeki}|NorimitsuKadowaki{KadowakiNorimitsu}|SyuichiOta{OtaSyuichi}|TakeshiMaeda{MaedaTakeshi}|MasayoshiMasuko{MasukoMasayoshi}|KazunoriMurai{MuraiKazunori}|TatsuyaImi{ImiTatsuya}|MakotoOnizuka{OnizukaMakoto}|HitoshiHanamoto{HanamotoHitoshi}|YoshihiroOka{OkaYoshihiro}|HaruoSugiyama{SugiyamaHaruo}|KuniyoshiNiwa{NiwaKuniyoshi}|RyokoNakagawa{NakagawaRyoko}|MizuhaKanaya{KanayaMizuha}|YuichiIshikawa{IshikawaYuichi}|Hee-JeKim{KimHee-Je}|RadovanVrhovac{VrhovacRadovan}|ElzbietaPatkowska{PatkowskaElzbieta}|PavelZak{ZakPavel}|Po-NanWang{WangPo-Nan}|JorgeCortes{CortesJorge}|MikkaelSekeres{SekeresMikkael}|HervéDombret{DombretHervé}|SergioAmadori{AmadoriSergio}|JianxiangWang{WangJianxiang}|RichardSchlenk{SchlenkRichard}|AlexanderPerl{PerlAlexander}|MitsuhiroYazawa{YazawaMitsuhiro}|JaimeConnollyRohrbach{ConnollyRohrbachJaime}|VenkatThodima{ThodimaVenkat}|LiLiu{LiuLi}|KarimaImadalou{ImadalouKarima}|AkashNahar{NaharAkash}|KristyBurns{BurnsKristy}____Oral Session 1-9BAML: Clinical 1____Phase 2 study of oral azacitidine maintenance for acute myeloid leukemia in first remission in Japan|Phase 1/2 study of the Menin-MLL inhibitor enzomenib in Japanese patients with R/R acute leukemia|Efficacy and safety of CPX-351 by age: subgroup analysis of Japanese P1/2 and global P3|Prognostic impact of HSCT and co-mutations in TP53-mutated AML: analysis from the WT1-AM-04 Study|Real-world safety of venetoclax in unfit AML: final results from all-case PMS in Japan|Correlation of baseline gene mutations with quizartinib efficacy in 1st line FLT3-ITD+ AML patients

O1-9B

Oral Session 1-9B
AML: Clinical 1

Chair：Hisayuki Yokoyama

NaotoTakahashi{TakahashiNaoto}|MichikoIchii{IchiiMichiko}|YosukeMinami{MinamiYosuke}|FumisatoTakagi{TakagiFumisato}|TakaakiOno{OnoTakaaki}|TomoikuTakaku{TakakuTomoiku}____ChikashiYoshida{YoshidaChikashi}____JorgeE.Cortes{CortesJorgeE.}|JianxiangWang{WangJianxiang}|Dong-WookKim{KimDong-Wook}|DennisDongHwanKim{KimDennisDongHwan}|JiriMayer{MayerJiri}|YeowTeeGoh{GohYeowTee}|PhilippleCoutre{CoutrePhilipple}|GabrielEtienne{EtienneGabriel}|InhoKim{KimInho}|FeliceBombaci{BombaciFelice}|GhayasC.Issa{IssaGhayasC.}|RichardA.Larson{LarsonRichardA.}|ShrutiKapoor{KapoorShruti}|KamelMalek{MalekKamel}|LillianYau{YauLillian}|AndreasHochhaus{HochhausAndreas}|TimothyP.Hughes{HughesTimothyP.}|YoshikaneKikushige{KikushigeYoshikane}|HirohisaNakamae{NakamaeHirohisa}|TatsunoriGoto{GotoTatsunori}|AkihiroTomita{TomitaAkihiro}|SatoshiIto{ItoSatoshi}|TakanoriTeshima{TeshimaTakanori}|KeitaKirito{KiritoKeita}|TakayukiIkezoe{IkezoeTakayuki}|KaoruHatano{HatanoKaoru}|YasunoriUeda{UedaYasunori}|HirokazuTanaka{TanakaHirokazu}|NobuhiroHiramoto{HiramotoNobuhiro}|RyoheiOsako{OsakoRyohei}|MakotoAoki{AokiMakoto}|RajendraJinwal{JinwalRajendra}|NaotoTakahashi{TakahashiNaoto}|KentaroFukushima{FukushimaKentaro}|TakeshiKondo{KondoTakeshi}|SeiichiroKatagiri{KatagiriSeiichiro}|BriannaHoffner{HoffnerBrianna}|QiWang{WangQi}|YangYingsi{YingsiYang}|HelenCollins{CollinsHelen}|TakaakiOno{OnoTakaaki}|YosukeMinami{MinamiYosuke}|ChiakiNakaseko{NakasekoChiaki}|NoriyoshiIriyama{IriyamaNoriyoshi}|KatsumichiFujimaki{FujimakiKatsumichi}|KazuhikoKakihana{KakihanaKazuhiko}|YojiOgasawara{OgasawaraYoji}|MasayaOkada{OkadaMasaya}|TetsuzoTauchi{TauchiTetsuzo}|YoshikoAtsuta{AtsutaYoshiko}|RitsuroSuzuki{SuzukiRitsuro}|KazuhitoYamamoto{YamamotoKazuhito}|ShigekiOhtake{OhtakeShigeki}|ToshihiroMiyamoto{MiyamotoToshihiro}|KazunoriOhnishi{OhnishiKazunori}|EmikoSakaida{SakaidaEmiko}|ShinFujisawa{FujisawaShin}|YukioKobayashi{KobayashiYukio}|TatsuyaKawaguchi{KawaguchiTatsuya}|MasahiroKizaki{KizakiMasahiro}|HitoshiKiyoi{KiyoiHitoshi}|YasushiMiyazaki{MiyazakiYasushi}|ItaruMatsumura{MatsumuraItaru}|TakashiOkada{OkadaTakashi}|KohjinSuzuki{SuzukiKohjin}|EriMatsuki{MatsukiEri}|AtsushiSatake{SatakeAtsushi}|MasahideYamamoto{YamamotoMasahide}|ChikashiYoshida{YoshidaChikashi}|KazunoriMurai{MuraiKazunori}|DennisKim{KimDennis}____Oral Session 1-9CCML: Clinical Trial____Asciminib in newly diagnosed CML: 96-week analysis of early molecular responders in ASC4FIRST|ASC4FIRST 96-week subgroup analysis: Asciminib in Japanese patients with newly diagnosed CML|ELVN-001 for the treatment of CML with and without T315I mutation: a phase 1 trial in Japan|The ELTS score predicts failure-free survival in CML patients in the era of second-generation TKIs|Early prediction of MR4.5 achievement and durability in CML treated with second-generation TKIs|Propensity score-matched comparison of asciminib and ponatinib in Japanese patients with CML

O1-9C

Oral Session 1-9C
CML: Clinical Trial

Chair：Chikashi Yoshida

MasuhoSaburi{SaburiMasuho}|KohTeshima{TeshimaKoh}|SoHattori{HattoriSo}|MaiFujita{FujitaMai}|YukimasaKobayashi{KobayashiYukimasa}____NoriyoshiIriyama{IriyamaNoriyoshi}____TakumiNishikawa{NishikawaTakumi}|KuniakiMaehara{MaeharaKuniaki}|HiroyukiTakata{TakataHiroyuki}|YasuhikoMiyazaki{MiyazakiYasuhiko}|MasanoriSakata{SakataMasanori}|KazuhiroKohno{KohnoKazuhiro}|YukoOOgata{OgataYukoO}|TakamiHaruyama{HaruyamaTakami}|EiichiOhtsuka{OhtsukaEiichi}|AikaNasu{NasuAika}|MichitakaYamaguchi{YamaguchiMichitaka}|RikiSekine{SekineRiki}|YukaTaniguchi{TaniguchiYuka}|KeiOikawa{OikawaKei}|DaigoMichimata{MichimataDaigo}|NorifumiSugawara{SugawaraNorifumi}|HiroyukiHamada{HamadaHiroyuki}|KazunoriMurai{MuraiKazunori}|HiroshiUreshino{UreshinoHiroshi}|ShinyaKimura{KimuraShinya}|YoshinoriOdaka{OdakaYoshinori}|RyoHashikawa{HashikawaRyo}|NatsukiNorioka{NoriokaNatsuki}|IkuyoTsutsumi{TsutsumiIkuyo}|TakuyaKomeno{KomenoTakuya}|ChikashiYoshida{YoshidaChikashi}|KeisukeKidoguchi{KidoguchiKeisuke}|HarunaOumaru{OumaruHaruna}|TatsuyaMihashi{MihashiTatsuya}|RyoYanagiya{YanagiyaRyo}|KanaKusaba{KusabaKana}|HarunaSano{SanoHaruna}|YoheiHarada{HaradaYohei}|HidekazuItamura{ItamuraHidekazu}|ShoOkamoto{OkamotoSho}|MarikoYoshimura{YoshimuraMariko}|HirooKatsuya{KatsuyaHiroo}|ToshihikoAndo{AndoToshihiko}|RintaroNegishi{NegishiRintaro}|AyakaWatanabe{WatanabeAyaka}|NozomiKudo{KudoNozomi}|KenFujimori{FujimoriKen}|TakeshiNonaka{NonakaTakeshi}|YutaNakadoi{NakadoiYuta}|MisakoYoshikawa{YoshikawaMisako}|DaichiMitsui{MitsuiDaichi}|TakahiroMikawa{MikawaTakahiro}|MasakiIino{IinoMasaki}____Oral Session 1-9DCML: TKI and Asciminib____Retrospective study of clinical outcomes of bosutinib in untreated chronic myeloid leukemia|Long-term follow-up analysis of the DAVLEC study at a single institution|Real-world treatment outcomes of asciminib in chronic myeloid leukemia: a retrospective study|Safety and efficacy of asciminib in patients with chronic myeloid leukemia beyond the third line|Real-world treatment-free remission after TKI discontinuation in CML: a single-center experience

O1-9D

Oral Session 1-9D
CML: TKI and Asciminib

Chair：Noriyoshi Iriyama

TomoyaMaeda{MaedaTomoya}____HirokiYamaguchi{YamaguchiHiroki}________Educational Lecture 1-10-1Recent insights and clinical issues in acute myeloid leukemia in older adults____Recent insights and clinical issues in acute myeloid leukemia in older adults

EL1-10-1

Educational Lecture 1-10-1
Recent insights and clinical issues in acute myeloid leukemia in older adults

Chair：Hiroki Yamaguchi

Speaker：Tomoya Maeda

YasunobuNagata{NagataYasunobu}____YuichiIshikawa{IshikawaYuichi}________Educational Lecture 1-10-2Venetoclax resistance and molecular abnormalities in AML____Venetoclax resistance and molecular abnormalities in AML

EL1-10-2

Educational Lecture 1-10-2
Venetoclax resistance and molecular abnormalities in AML

Chair：Yuichi Ishikawa

Speaker：Yasunobu Nagata

DaisukeTomizawa{TomizawaDaisuke}____HiroshiMoritake{MoritakeHiroshi}________Educational Lecture 1-10-3Expert consensus guidelines for pediatric acute myeloid leukemia____Expert consensus guidelines for pediatric acute myeloid leukemia

EL1-10-3

Educational Lecture 1-10-3
Expert consensus guidelines for pediatric acute myeloid leukemia

Chair：Hiroshi Moritake

Speaker：Daisuke Tomizawa

Ken-ichiMatsuoka{MatsuokaKen-ichi}____KojiNagafuji{NagafujiKoji}________Educational Lecture 1-10-4Recent advances in the treatment of acute lymphoblastic leukemia____Recent advances in the treatment of acute lymphoblastic leukemia

EL1-10-4

Educational Lecture 1-10-4
Recent advances in the treatment of acute lymphoblastic leukemia

Chair：Koji Nagafuji

Speaker：Ken-ichi Matsuoka

KeijiOkinaka{OkinakaKeiji}____YukiAsano-Mori{Asano-MoriYuki}________Educational Lecture 1-10-5Immunization of adult hematopoietic stem cell transplant recipients: current recommendations and clinical application____Immunization of adult hematopoietic stem cell transplant recipients: current recommendations and clinical application

EL1-10-5

Educational Lecture 1-10-5
Immunization of adult hematopoietic stem cell transplant recipients: current recommendations and clinical application

Chair：Yuki Asano-Mori

Speaker：Keiji Okinaka

TomoyasuJo{JoTomoyasu}____KaoruKahata{KahataKaoru}________Educational Lecture 1-10-6CAR-T cell therapy in clinical practice____CAR-T cell therapy in clinical practice

EL1-10-6

Educational Lecture 1-10-6
CAR-T cell therapy in clinical practice

Chair：Kaoru Kahata

Speaker：Tomoyasu Jo

KeisukeWatanabe{WatanabeKeisuke}____HarukoTashiro{TashiroHaruko}________Educational Lecture 1-10-7Clinical development of genetically modified T cell therapies____Clinical development of genetically modified T cell therapies

EL1-10-7

Educational Lecture 1-10-7
Clinical development of genetically modified T cell therapies

Chair：Haruko Tashiro

Speaker：Keisuke Watanabe

YosukeTogashi{TogashiYosuke}____YasuyukiArai{AraiYasuyuki}________Educational Lecture 1-10-8T cell exhaustion in the tumor microenvironment____T cell exhaustion in the tumor microenvironment

EL1-10-8

Educational Lecture 1-10-8
T cell exhaustion in the tumor microenvironment

Chair：Yasuyuki Arai

Speaker：Yosuke Togashi

FumikoIto{ItoFumiko}|MasatakaKuwana{KuwanaMasataka}|KatsumichiFujimaki{FujimakiKatsumichi}|ToshikiYamada{YamadaToshiki}|KentaIwase{IwaseKenta}|MidoriIshiyama{IshiyamaMidori}____ShugoKowata{KowataShugo}____YoshinoriShinohara{ShinoharaYoshinori}|RieMasai{MasaiRie}|TomokoYoshioka{YoshiokaTomoko}|NaotoTakahashi{TakahashiNaoto}|KazunoriAbe{AbeKazunori}|MaFuruya{FuruyaMa}|MariYato{YatoMari}|SoSaotome{SaotomeSo}|TakaakiTakeda{TakedaTakaaki}|KotaKawabata{KawabataKota}|AyakoBohno{BohnoAyako}|YukiNakajima{NakajimaYuki}|HideakiNakajima{NakajimaHideaki}|ToshikiFukunaga{FukunagaToshiki}|NaokiHayase{HayaseNaoki}|HisashiTsurumi{TsurumiHisashi}|ShunsukeYui{YuiShunsuke}|YuyaKishida{KishidaYuya}|ToshioAsayama{AsayamaToshio}|MasamichiIsobe{IsobeMasamichi}|YasunobuNagata{NagataYasunobu}|SatoshiWakita{WakitaSatoshi}|KazutakaNakayama{NakayamaKazutaka}|HirokiYamaguchi{YamaguchiHiroki}|KentaroYoshinaga{YoshinagaKentaro}|SatoruItoi{ItoiSatoru}|AzusaMorimoto{MorimotoAzusa}|MayaHoshi{HoshiMaya}|HirokoSato{SatoHiroko}|YusukeYoshinaga{YoshinagaYusuke}|SatokoOsanai{OsanaiSatoko}|NorinaTanaka{TanakaNorina}|AkihitoShinohara{ShinoharaAkihito}|SachikoSeo{SeoSachiko}____Oral Session 1-11AImmune Thrombocytopenia/Fostamatinib____Fostamatinib therapy for refractory immune thrombocytopenia|Post-marketing surveillance of fostamatinib in patients with ITP: Interim report|Efficacy and safety of fostamatinib for patients with immune thrombocytopenia|Efficacy and safety of fostamatinib for refractory immune thrombocytopenia in our hospital|Efficacy and safety of fostamatinib in chronic ITP: single-center retrospective study|The efficacy of fostamatinib for immune thrombocytopenia: a retrospective single-center study

O1-11A

Oral Session 1-11A
Immune Thrombocytopenia/Fostamatinib

Chair：Shugo Kowata

MasakoNishikawa{NishikawaMasako}|AikaNasu{NasuAika}|YukariSakurai{SakuraiYukari}|NaokoHiranuma{HiranumaNaoko}|NarukoSuzuki{SuzukiNaruko}|TaitoKiwada{KiwadaTaito}____HisashiKato{KatoHisashi}____QianYu{YuQian}|YuqiZhou{ZhouYuqi}|HongqianZhang{ZhangHongqian}|HuidongWang{WangHuidong}|JunyuChen{ChenJunyu}|TakeyaTsutsumi{TsutsumiTakeya}|MakotoKurano{KuranoMakoto}|YutakaYatomi{YatomiYutaka}|ShenghongJu{JuShenghong}|KeisukeGoda{GodaKeisuke}|KohTeshima{TeshimaKoh}|MichitakaYamaguchi{YamaguchiMichitaka}|RikiSekine{SekineRiki}|YukaTaniguchi{TaniguchiYuka}|KeiOikawa{OikawaKei}|DaigoMichimata{MichimataDaigo}|NorifumiSugawara{SugawaraNorifumi}|HiroyukiHamada{HamadaHiroyuki}|TsutomuSakuma{SakumaTsutomu}|KazunoriMurai{MuraiKazunori}|NaoyaMatsumoto{MatsumotoNaoya}|TakeoSarashina{SarashinaTakeo}|SatoruTakahashi{TakahashiSatoru}|KoIdeguchi{IdeguchiKo}|MarikoTanabe{TanabeMariko}|KazuhiroBandai{BandaiKazuhiro}|KensukeFujiwara{FujiwaraKensuke}|TakahitoKawata{KawataTakahito}|AkiraTamekane{TamekaneAkira}|MitsumasaWatanabe{WatanabeMitsumasa}|TomokiFujii{FujiiTomoki}|ReikaIto{ItoReika}|YasuhikoHarada{HaradaYasuhiko}|JunjiHiraga{HiragaJunji}|MotoyasuKanazawa{KanazawaMotoyasu}|TaeNinomiya{NinomiyaTae}|NaoYoshida{YoshidaNao}|DaikiHarada{HaradaDaiki}|TomoyaArakawa{ArakawaTomoya}|SomiOzaki{OzakiSomi}|HarukiKoketsu{KoketsuHaruki}|TomoyoshiWakayama{WakayamaTomoyoshi}|HitomiSawa{SawaHitomi}|ToshiyasuSakai{SakaiToshiyasu}|KotaroMiyao{MiyaoKotaro}|YuichiroInagaki{InagakiYuichiro}|MasashiSawa{SawaMasashi}____Oral Session 1-11BPlatelet/Immune Thrombocytopenia____Image analysis of circulating platelets and their association with metabolic disorders in COVID-19|Acquired amegakaryocytic thrombocytopenia following infectious mononucleosis: a case report|Immature platelet count and treatment response in pediatric acute immune thrombocytopenia|Impact of 1st-line high-dose dexamethasone and 2nd-line rituximab on treatment-free remission in ITP|Risk of thrombosis in ITP treatment: single-center retrospective study|Increased thrombosis with thrombopoietin receptor agonists in idiopathic thrombocytopenic purpura

O1-11B

Oral Session 1-11B
Platelet/Immune Thrombocytopenia

Chair：Hisashi Kato

YuichiroInagaki{InagakiYuichiro}|AkihiroUmakoshi{UmakoshiAkihiro}|ShotaYokoyama{YokoyamaShota}|KeiNakajima{NakajimaKei}|ManatoSugisaki{SugisakiManato}|YuMizoguchi{MizoguchiYu}____YokoEdahiro{EdahiroYoko}____NaoYoshida{YoshidaNao}|MotoyasuKanazawa{KanazawaMotoyasu}|TaeNinomiya{NinomiyaTae}|DaikiHarada{HaradaDaiki}|TaitoKiwada{KiwadaTaito}|TomoyaArakawa{ArakawaTomoya}|SomiOzaki{OzakiSomi}|HarukiKoketsu{KoketsuHaruki}|TomoyoshiWakayama{WakayamaTomoyoshi}|HitomiSawa{SawaHitomi}|ToshiyasuSakai{SakaiToshiyasu}|KotaroMiyao{MiyaoKotaro}|MasashiSawa{SawaMasashi}|KimimoriKamijo{KamijoKimimori}|TomohisaMachida{MachidaTomohisa}|MasamiImakita{ImakitaMasami}|YasuhitoNannya{NannyaYasuhito}|TsuyoshiKamae{KamaeTsuyoshi}|YudaiYamaguchi{YamaguchiYudai}|TomohiroYamakawa{YamakawaTomohiro}|KentaroWakasa{WakasaKentaro}|YumaSakamoto{SakamotoYuma}|KeishiroKawai{KawaiKeishiro}|HidetoHyuga{HyugaHideto}|ErikoHosokawa{HosokawaEriko}|AyatoNakadate{NakadateAyato}|MinoriMatsuura{MatsuuraMinori}|JunSuzuki{SuzukiJun}|TakumaKumagai{KumagaiTakuma}|MegumiSuzuki{SuzukiMegumi}|MegumiYamada{YamadaMegumi}|TakeoYamamoto{YamamotoTakeo}|IchiroKawashima{KawashimaIchiro}|KeitaKirito{KiritoKeita}|KwanEeOh{OhKwanEe}|KenjiImamura{ImamuraKenji}|TakatomoYoshida{YoshidaTakatomo}|KohtaroToyama{ToyamaKohtaro}|EoToriyama{ToriyamaEo}|KyokoMinamino{MinaminoKyoko}|YukoKirino{KirinoYuko}|AzusaKojima{KojimaAzusa}|YuichiYamada{YamadaYuichi}|MikiHashimoto{HashimotoMiki}|HikaruSakamoto{SakamotoHikaru}|MasahikoChiwata{ChiwataMasahiko}|TakeharuKato{KatoTakeharu}|MasatakaTaguchi{TaguchiMasataka}|MakikoHorai{HoraiMakiko}|ShinyaSato{SatoShinya}|KojiAndo{AndoKoji}|YasushiMiyazaki{MiyazakiYasushi}____Oral Session 1-11CMPN: Clinical 1____The clinical course and treatment selection for polycythemia vera|Myeloid sarcoma transformed from PV with distinct genomic profiles analyzed by NGS|Clinical impact of neutrophil/lymphocyte ratio (NLR) in polycythemia vera patients|Development of myelofibrosis during treatment with anagrelide in essential thrombocythemia patients|Disappearance of del(7q) in myelofibrosis with myeloma treated by lenalidomide and elotuzumab|A case of MLN with FGFR1 fusion gene that underwent allo-HSCT in a remission state with pemigatinib

O1-11C

Oral Session 1-11C
MPN: Clinical 1

Chair：Yoko Edahiro

NoriakiTachi{TachiNoriaki}|KenSasaki{SasakiKen}|KokiUeda{UedaKoki}|SaoriMiura{MiuraSaori}|YumaSakamoto{SakamotoYuma}|EikoOhya{OhyaEiko}____TakaakiMaekawa{MaekawaTakaaki}____TakaakiMaekawa{MaekawaTakaaki}|EmiKemmoku{KemmokuEmi}|TakutoShonai{ShonaiTakuto}|KotaKawasaki{KawasakiKota}|TakehiroSone{SoneTakehiro}|KoheiTakada{TakadaKohei}|HirakuOgata{OgataHiraku}|KeitaSaito{SaitoKeita}|ToshikuniKawamura{KawamuraToshikuni}|ShoichiroKato{KatoShoichiro}|YukikoOsawa{OsawaYukiko}|ShinichiKobayashi{KobayashiShinichi}|FumihikoKimura{KimuraFumihiko}|HirofumiTakano{TakanoHirofumi}|TadayukiOgawa{OgawaTadayuki}|YosukeMasamoto{MasamotoYosuke}|MineoKurokawa{KurokawaMineo}|YukaSato{SatoYuka}|KeijiMinakawa{MinakawaKeiji}|SaoriMiura{MiuraSaori}|KazuhikoIkeda{IkedaKazuhiko}|KokiUeda{UedaKoki}|TomofumiMisaka{MisakaTomofumi}|ShunsukeMiura{MiuraShunsuke}|MasatoMatsuda{MatsudaMasato}|YasuchikaTakeishi{TakeishiYasuchika}|KeiNakajima{NakajimaKei}|KeishiroKawai{KawaiKeishiro}|HidetoHyuga{HyugaHideto}|ErikoHosokawa{HosokawaEriko}|AyatoNakadate{NakadateAyato}|MinoriMatsuura{MatsuuraMinori}|JunSuzuki{SuzukiJun}|TakumaKumagai{KumagaiTakuma}|MegumiSuzuki{SuzukiMegumi}|MegumiYamada{YamadaMegumi}|TakeoYamamoto{YamamotoTakeo}|IchiroKawashima{KawashimaIchiro}|KeitaKirito{KiritoKeita}|YukaSugimoto{SugimotoYuka}|KeikiNagaharu{NagaharuKeiki}|IsaoTawara{TawaraIsao}|KyokoImanaka{ImanakaKyoko}|KohshiOhishi{OhishiKohshi}____Oral Session 1-11DMPN: Basic____CCL22 and TIMP-1 induce fibrocytes in secondary myelofibrosis associated with lymphoid malignancies|eIF4B is a critical mediator in myelofibrosis and a therapeutic target via translation inhibition|Mice with Calr mutation and Ezh2 deletion develop fatal myeloid neoplasms|Distinct energy metabolism in JAK2-mutant platelets may contribute to their impaired aggregation|Elevation of ATF4 in megakaryocytes in post-ET-MF patients after treatment with anagrelide|Altered serum inflammatory cytokines and Tenascin-C in myeloproliferative neoplasms

O1-11D

Oral Session 1-11D
MPN: Basic

Chair：Takaaki Maekawa

HuaZhang{ZhangHua}|JakrawadeeJulamanee{JulamaneeJakrawadee}|ZiweiLiao{LiaoZiwei}|Seok-GooCho{ChoSeok-Goo}|SeigiOshima{OshimaSeigi}|KazukiAsazuma{AsazumaKazuki}____YoshihiroInamoto{InamotoYoshihiro}____XinyuWan{WanXinyu}|WenjieLi{LiWenjie}|JiaoyangCai{CaiJiaoyang}|XiaominYang{YangXiaomin}|LiuYang{YangLiu}|JingYang{YangJing}|TianyiWang{WangTianyi}|ZichaoZhou{ZhouZichao}|MengSu{SuMeng}|JingZhang{ZhangJing}|JuanQian{QianJuan}|KangAn{AnKang}|ChengjuanLuo{LuoChengjuan}|LixiaDing{DingLixia}|LiliSong{SongLili}|WenhuaShi{ShiWenhua}|YanjingTang{TangYanjing}|BenshangLi{LiBenshang}|ChengCheng{ChengCheng}|JianHua{HuaJian}|XuefengLuo{LuoXuefeng}|Ching-HonPui{PuiChing-Hon}|PanaratNoiperm{NoipermPanarat}|WatsamonUraiwan{UraiwanWatsamon}|KajornkiatManeechai{ManeechaiKajornkiat}|ChaweewanPunsuk{PunsukChaweewan}|PhakapornUdomsak{UdomsakPhakaporn}|PornpunSripornsawan{SripornsawanPornpun}|UmapornYam-Ubon{Yam-UbonUmaporn}|ThirachitChotsampancharoen{ChotsampancharoenThirachit}|WannakornKhopanlert{KhopanlertWannakorn}|SupannikarTawinwung{TawinwungSupannikar}|KoramitSuppipat{SuppipatKoramit}|SeitaroTerakura{TerakuraSeitaro}|WeinaZhang{ZhangWeina}|FeimeiKuang{KuangFeimei}|YuxuanLuo{LuoYuxuan}|Keon-IlIm{ImKeon-Il}|NayounKim{KimNayoun}|Jun-SeokLee{LeeJun-Seok}|Woo-TaeCho{ChoWoo-Tae}|TomoyasuJo{JoTomoyasu}|YasuyukiArai{AraiYasuyuki}|ToshioKitawaki{KitawakiToshio}|NoriyoshiYoshinaga{YoshinagaNoriyoshi}|TakashiSakamoto{SakamotoTakashi}|JunyaKanda{KandaJunya}|KouheiYamashita{YamashitaKouhei}|AkifumiTakaori{TakaoriAkifumi}|MidoriIshii{IshiiMidori}|ShintaroKinoshita{KinoshitaShintaro}|ErinaHosoya{HosoyaErina}|YoshikiFurukawa{FurukawaYoshiki}|ToruMitsumori{MitsumoriToru}|ErikoSato{SatoEriko}|HinaTakano{TakanoHina}|NaokiWatanabe{WatanabeNaoki}|YutakaTsukune{TsukuneYutaka}|HajimeYasuda{YasudaHajime}|YasuharuHamano{HamanoYasuharu}|MakotoSasaki{SasakiMakoto}|JunAndo{AndoJun}|MikiAndo{AndoMiki}____Oral Session 1-13ACAR-T: Clinic 1____Safety and efficacy of bicistronic CD19/CD22 CAR T cell therapy in treatment of childhood R/R B-ALL|CD28/CD40 signaling domain potentiates CD19CAR efficacy and stemness in r/r B-ALL and B-NHL patients|CAR-T cell therapy for pediatric R/R B-ALL in China: a real-world study of efficacy and safety|Multi-virus specific memory T cells targeting CMV, BKV, and EBV in post-HSCT viral infections|Efficacy and safety of idecabtagene vicleucel in relapsed/refractory multiple myeloma|A single center retrospective study of CD19-directed CAR-T therapy using 3 products for LBCL

O1-13A

Oral Session 1-13A
CAR-T: Clinic 1

Chair：Yoshihiro Inamoto

YuYagi{YagiYu}|RyoHanajiri{HanajiriRyo}|KyokoYoshihara{YoshiharaKyoko}|JunichiKato{KatoJunichi}|SeiyaBamba{BambaSeiya}|YasuyukiArai{AraiYasuyuki}____SatoshiYoshihara{YoshiharaSatoshi}____YusukeKanemasa{KanemasaYusuke}|ToshikiTerao{TeraoToshiki}|MotohiroKato{KatoMotohiro}|TomoyasuJo{JoTomoyasu}|TatsuShimoyama{ShimoyamaTatsu}|ToshioKitawaki{KitawakiToshio}|SeitaroTerakura{TerakuraSeitaro}|NorikoDoki{DokiNoriko}|SatoshiYoshihara{YoshiharaSatoshi}|NobuharuFujii{FujiiNobuharu}|NorikoIwaki{IwakiNoriko}|GoYamamoto{YamamotoGo}|MasatoshiSakurai{SakuraiMasatoshi}|ToshihiroMatsukawa{MatsukawaToshihiro}|EmikoSakaida{SakaidaEmiko}|HaryoonKim{KimHaryoon}|KeisukeKataoka{KataokaKeisuke}|HidekiGoto{GotoHideki}|YoshikoAtsuta{AtsutaYoshiko}|KojiKato{KatoKoji}|HiroyukiTakahashi{TakahashiHiroyuki}|YoshihiroInamoto{InamotoYoshihiro}|ShinichiMakita{MakitaShinichi}|KazuyukiShimada{ShimadaKazuyuki}|KojiIzutsu{IzutsuKoji}|TakahideAra{AraTakahide}|KeisukeTanaka{TanakaKeisuke}|MarieOhbiki{OhbikiMarie}|SakiTakahashi{TakahashiSaki}|TomokoKumamoto{KumamotoTomoko}|YoshiyukiFujita{FujitaYoshiyuki}|FuyukiYamagata{YamagataFuyuki}|ShutaroFujioka{FujiokaShutaro}|NaruTomigaki{TomigakiNaru}|RyoIkunari{IkunariRyo}|NobutoUtsunomiya{UtsunomiyaNobuto}|MamiSamori{SamoriMami}|AtsushiKatayama{KatayamaAtsushi}|MasahiroTeramoto{TeramotoMasahiro}|TakayukiInoue{InoueTakayuki}|KatsujiKaida{KaidaKatsuji}|TazukoTokugawa{TokugawaTazuko}|AkihiroSawada{SawadaAkihiro}|HirokiSugiyama{SugiyamaHiroki}|HitomiOnomoto{OnomotoHitomi}|JunkoIkemoto{IkemotoJunko}|SatoshiHigasa{HigasaSatoshi}|HiroyaTamaki{TamakiHiroya}|TatsuyaKonishi{KonishiTatsuya}|TakatsuguHonda{HondaTakatsugu}|MasakiMaruta{MarutaMasaki}|ShogoNabe{NabeShogo}|YuyaMasuda{MasudaYuya}|YukihiroMiyazaki{MiyazakiYukihiro}|YasukazuDoi{DoiYasukazu}|YasunoriTakasuka{TakasukaYasunori}|JunYamanouchi{YamanouchiJun}|ToshikiOchi{OchiToshiki}|KatsutoTakenaka{TakenakaKatsuto}|YasuyukiArai{AraiYasuyuki}|NoriyoshiYoshinaga{YoshinagaNoriyoshi}|TakashiSakamoto{SakamotoTakashi}|JunyaKanda{KandaJunya}|MomokoNishikori{NishikoriMomoko}|KouheiYamashita{YamashitaKouhei}|AkifumiTakaoriKondo{TakaoriKondoAkifumi}|DaisukeKaji{KajiDaisuke}|TakayukiSato{SatoTakayuki}____Oral Session 1-13BCAR-T: Clinic 2____Longitudinal improvement in outcomes of CAR-T cell therapy for large B-cell lymphoma in Japan|Site-specific impact of extranodal disease on CAR T therapy outcomes in DLBCL|CAR-T cell therapy for DLBCL: CAR-T as second-line therapy vs. ≧ third-line therapy|Bystander CAR-CD8+ T cells in a CAR-T cell product can augment bispecific antibody responses|Elucidation of the triggers underlying CAR-T therapy-related hypofibrinogenemia|Association of pre-infusion renal function with CRS following CAR-T cell therapy for LBCL

O1-13B

Oral Session 1-13B
CAR-T: Clinic 2

Chair：Satoshi Yoshihara

NoriyoshiYoshinaga{YoshinagaNoriyoshi}|IrohaMorita{MoritaIroha}|KosukeTakano{TakanoKosuke}|HirotaroSakaki{SakakiHirotaro}|MizukiWatanabe{WatanabeMizuki}____MakotoMurata{MurataMakoto}____MakotoIwasaki{IwasakiMakoto}|KojiKato{KatoKoji}|FumihikoKimura{KimuraFumihiko}|MasahiroHirayama{HirayamaMasahiro}|MinoruKanaya{KanayaMinoru}|SatokoMorishima{MorishimaSatoko}|NaoyukiUchida{UchidaNaoyuki}|NorikoDoki{DokiNoriko}|TakahiroFukuda{FukudaTakahiro}|YoshinobuKanda{KandaYoshinobu}|TetsuyaNishida{NishidaTetsuya}|YutaHasegawa{HasegawaYuta}|ShinichiKako{KakoShinichi}|MasatsuguTanaka{TanakaMasatsugu}|MineoKurokawa{KurokawaMineo}|TatsuoIchinohe{IchinoheTatsuo}|MakotoOnizuka{OnizukaMakoto}|YoshikoAtsuta{AtsutaYoshiko}|JunyaKanda{KandaJunya}|SungGiChi{ChiSungGi}|TomokiNaito{NaitoTomoki}|DaisukeIkeda{IkedaDaisuke}|NaokoHosono{HosonoNaoko}|TakahiroYamauchi{YamauchiTakahiro}|KentaroFukushima{FukushimaKentaro}|GoichiYoshimoto{YoshimotoGoichi}|MakotoYoshimitsu{YoshimitsuMakoto}|ShigeruKusumoto{KusumotoShigeru}|NaotoTakahashi{TakahashiNaoto}|EmikoSakaida{SakaidaEmiko}|KensukeUsuki{UsukiKensuke}|KeisukeTanaka{TanakaKeisuke}|AkifumiTakaoriKondo{TakaoriKondoAkifumi}|YosukeMinami{MinamiYosuke}|MasaharuTamaki{TamakiMasaharu}|ShuntoKawamura{KawamuraShunto}|SeitaroTerakura{TerakuraSeitaro}|YoshitakaInoue{InoueYoshitaka}|DaiKeino{KeinoDai}|NoboruAsada{AsadaNoboru}|MasashiSawa{SawaMasashi}|KojiKawamura{KawamuraKoji}|MarieOhbiki{OhbikiMarie}|KimikazuYakushijin{YakushijinKimikazu}|HidekiNakasone{NakasoneHideki}|MisuzuSato{SatoMisuzu}|AyanoShirai{ShiraiAyano}|MamiUmemoto{UmemotoMami}|HidenoriHayashi{HayashiHidenori}|NatsukiKawamata{KawamataNatsuki}|KazukiNagao{NagaoKazuki}|KaiKuroiwa{KuroiwaKai}|HinakoNarita{NaritaHinako}|ReikoOkamura{OkamuraReiko}|ShotaroShimada{ShimadaShotaro}|MegumiWatanuki{WatanukiMegumi}|NanaArai{AraiNana}|KoujiYanagisawa{YanagisawaKouji}|KeiichiIezumi{IezumiKeiichi}|NorimichiHattori{HattoriNorimichi}|HidenoriTanaka{TanakaHidenori}|HisayukiYokoyama{YokoyamaHisayuki}|YutaKatayama{KatayamaYuta}|TetsuyaEto{EtoTetsuya}|MakotoMurata{MurataMakoto}|YasuhitoNannya{NannyaYasuhito}|TakahiroMaeda{MaedaTakahiro}|MotohiroKato{KatoMotohiro}____Oral Session 1-13CHSCT: Transplant Outcome 1____Optimal donor selection for patients with HLA-homozygous haplotypes in allogeneic transplantation|NGS-based risk stratification for decision making in SCT: insights from the HM01 and HM02 cohorts|The adverse effect of FtoM allogeneic hematopoietic cell transplantation varies by recipient age|Prognostic role of donor IL-10 and FOXP3 polymorphisms in allo-HSCT|Impact of specific HLA-C eplet mismatches on transplantation outcomes|Nationwide survey on physicians' views on integrating panel sequencing into transplant practice

O1-13C

Oral Session 1-13C
HSCT: Transplant Outcome 1

Chair：Makoto Murata

AsamiKataoka{KataokaAsami}|MasahiroAkimoto{AkimotoMasahiro}|TakuroKuriyama{KuriyamaTakuro}|HarukiKoketsu{KoketsuHaruki}|MasahoFukuda{FukudaMasaho}|NobuhikoImahashi{ImahashiNobuhiko}____HidekiNakasone{NakasoneHideki}____NoriyoshiYoshinaga{YoshinagaNoriyoshi}|YoshitakaInoue{InoueYoshitaka}|TomomiToubai{ToubaiTomomi}|NaoyukiUchida{UchidaNaoyuki}|ShigesaburoMiyakoshi{MiyakoshiShigesaburo}|YasufumiUehara{UeharaYasufumi}|NaoyukiAnzai{AnzaiNaoyuki}|ToshioWakayama{WakayamaToshio}|KazuyaIshiwata{IshiwataKazuya}|NorikoDoki{DokiNoriko}|MasahitoTokunaga{TokunagaMasahito}|KojiKawamura{KawamuraKoji}|TakahiroFukuda{FukudaTakahiro}|MarieOhbiki{OhbikiMarie}|YoshikoAtsuta{AtsutaYoshiko}|HidekiNakasone{NakasoneHideki}|KimikazuYakushijin{YakushijinKimikazu}|JunyaKanda{KandaJunya}|TakayoshiTachibana{TachibanaTakayoshi}|KengoKatsuki{KatsukiKengo}|ShotaArai{AraiShota}|TakaakiTakeda{TakedaTakaaki}|NatsukiHirose{HiroseNatsuki}|AkihikoIzumi{IzumiAkihiko}|MasatsuguTanaka{TanakaMasatsugu}|HideakiNakajima{NakajimaHideaki}|HidetakaNakagaki{NakagakiHidetaka}|ChieMatsuo{MatsuoChie}|ChiakiKubara{KubaraChiaki}|TaroTochigi{TochigiTaro}|MasayasuHayashi{HayashiMasayasu}|TetsuyaEto{EtoTetsuya}|ShuichiTaniguchi{TaniguchiShuichi}|KotaroMiyao{MiyaoKotaro}|MotoyasuKanazawa{KanazawaMotoyasu}|TaeNinomiya{NinomiyaTae}|NaoYoshida{YoshidaNao}|DaikiHarada{HaradaDaiki}|TaitoKiwada{KiwadaTaito}|TomoyaArakawa{ArakawaTomoya}|TomoyoshiWakayama{WakayamaTomoyoshi}|SomiOzaki{OzakiSomi}|HitomiSawa{SawaHitomi}|ToshiyasuSakai{SakaiToshiyasu}|YuichiroInagaki{InagakiYuichiro}|MasashiSawa{SawaMasashi}|TakayukiKatagiri{KatagiriTakayuki}|AyakoKawakami{KawakamiAyako}|TakumuTsuchida{TsuchidaTakumu}|MasakiMitobe{MitobeMasaki}|HodakaYonezawa{YonezawaHodaka}|TatsuyaSuwabe{SuwabeTatsuya}|KyokoFuse{FuseKyoko}|YasuhikoShibasaki{ShibasakiYasuhiko}|JunTakizawa{TakizawaJun}|HirohitoSone{SoneHirohito}|MasayoshiMasuko{MasukoMasayoshi}|TakaakiKonuma{KonumaTakaaki}|ShinichiKobayashi{KobayashiShinichi}|MizukiWatanabe{WatanabeMizuki}|SatoshiTakahashi{TakahashiSatoshi}|TetsuyaNishida{NishidaTetsuya}|ToshiroKawakita{KawakitaToshiro}|HirohisaNakamae{NakamaeHirohisa}|YasushiOnishi{OnishiYasushi}|MamikoSakata-Yanagimoto{Sakata-YanagimotoMamiko}|YoshinobuKanda{KandaYoshinobu}|FumihikoIshimaru{IshimaruFumihiko}|TatsuoIchinohe{IchinoheTatsuo}____Oral Session 1-13DHSCT: Transplant Outcome 2____Identification of prognostic factors in allo-HSCT in patients aged 70 years or older|Outcomes of cord blood transplantation using FM80TBI in elderly patients with acute myeloid leukemia|Outcomes of haploidentical stem cell transplantation using PTCy in patients aged ≥65 years|Single-center retrospective study of HLA-haploidentical vs matched unrelated PBSC transplantation|PTCY-haplo is an independent risk factor for relapse in allo-HSCT for high-risk MDS/AML/ALL|Exploring the potential of umbilical cord blood: Are matched related donors always the best choice?

O1-13D

Oral Session 1-13D
HSCT: Transplant Outcome 2

Chair：Hideki Nakasone

YuYagi{YagiYu}|ToruMiyajima{MiyajimaToru}____BelindaAvalos{AvalosBelinda}|MasatoshiSakurai{SakuraiMasatoshi}____YusukeKanemasa{KanemasaYusuke}|ToshikiTerao{TeraoToshiki}|MotohiroKato{KatoMotohiro}|TomoyasuJo{JoTomoyasu}|TatsuShimoyama{ShimoyamaTatsu}|ToshioKitawaki{KitawakiToshio}|SeitaroTerakura{TerakuraSeitaro}|NorikoDoki{DokiNoriko}|SatoshiYoshihara{YoshiharaSatoshi}|NobuharuFujii{FujiiNobuharu}|NorikoIwaki{IwakiNoriko}|GoYamamoto{YamamotoGo}|MasatoshiSakurai{SakuraiMasatoshi}|ToshihiroMatsukawa{MatsukawaToshihiro}|EmikoSakaida{SakaidaEmiko}|HaryoonKim{KimHaryoon}|KeisukeKataoka{KataokaKeisuke}|HidekiGoto{GotoHideki}|YoshikoAtsuta{AtsutaYoshiko}|KojiKato{KatoKoji}|DaigoHashimoto{HashimotoDaigo}|AsakoMoriki{MorikiAsako}|KeisukeKojima{KojimaKeisuke}|ShihoriTsukamoto{TsukamotoShihori}|TomoeIchiki{IchikiTomoe}|YumikaSaito{SaitoYumika}|WenyuLi{LiWenyu}|ZixuanZhang{ZhangZixuan}|ShinpeiHarada{HaradaShinpei}|HajimeSenjo{SenjoHajime}|YukiYokoi{YokoiYuki}|YutaHasegawa{HasegawaYuta}|HiroyukiOhigashi{OhigashiHiroyuki}|TakahideAra{AraTakahide}|KiminoriNakamura{NakamuraKiminori}|KojiTaniguchi{TaniguchiKoji}|TakanoriTeshima{TeshimaTakanori}____SETP1Cellular Immunotherapy for Hematological Malignancies____Longitudinal improvement in outcomes of CAR-T cell therapy for large B-cell lymphoma in Japan|GVHD-induced epigenetic imprinting promotes antigen presentation and apoptosis in IECs

SETP1

SETP1
Cellular Immunotherapy for Hematological Malignancies

KosukeMiki{MikiKosuke}|KensukeHachiya{HachiyaKensuke}____MehmetSamur{SamurMehmet}|TakeshiHarada{HaradaTakeshi}____KentaroWakasa{WakasaKentaro}|SatoshiYamamoto{YamamotoSatoshi}|TsuyoshiSato{SatoTsuyoshi}|TomoyaHarada{HaradaTomoya}|HajimeSenjo{SenjoHajime}|TakutoTachita{TachitaTakuto}|MasahiroChiba{ChibaMasahiro}|TetsuyukiIgarashi{IgarashiTetsuyuki}|TomoyukiSaga{SagaTomoyuki}|MasayoYamamoto{YamamotoMasayo}|KoheiOkada{OkadaKohei}|HidekiGoto{GotoHideki}|YukariTakeda{TakedaYukari}|MutsumiTakahata{TakahataMutsumi}|TatsuoOyake{OyakeTatsuo}|KatsuyaFujimoto{FujimotoKatsuya}|YoshihitoHaseyama{HaseyamaYoshihito}|KazuyaSato{SatoKazuya}|KazunoriMurai{MuraiKazunori}|ToshimichiIshihara{IshiharaToshimichi}|ShigekiIto{ItoShigeki}|TakanoriTeshima{TeshimaTakanori}|KohIzumiyama{IzumiyamaKoh}|FumitakaMuramatsu{MuramatsuFumitaka}|NobuyukiTakakura{TakakuraNobuyuki}____SETP2Molecular Pathogenesis of Multiple Myeloma____Multiple myeloma with 1% or more circulating plasma cells in peripheral blood has a poor prognosis|CXCL10+ bone marrow endothelial cells recruit myeloma cells into a localized immunosuppressive niche

SETP2

SETP2
Molecular Pathogenesis of Multiple Myeloma

YoshitakaMiyakawa{MiyakawaYoshitaka}|HirokiYamaguchi{YamaguchiHiroki}|Amita_RadhakrishnanNair{NairAmita_Radhakrishnan}|NonthakornHantrakun{HantrakunNonthakorn}|TanerTan{TanTaner}____HirokazuKashiwagi{KashiwagiHirokazu}____DavidJ.Kuter{KuterDavidJ.}|WaleedGhanima{GhanimaWaleed}|NicholaCooper{CooperNichola}|LeiZhang{ZhangLei}|YuHu{HuYu}|LuisaElenaMoralesGalindo{MoralesGalindoLuisaElena}|AnaLisaBasquiera{BasquieraAnaLisa}|ChuenWenTan{TanChuenWen}|GuraySaydam{SaydamGuray}|MarieLuiseHutter-Kronke{Hutter-KronkeMarieLuise}|ChatreeChai-Adisaksopha{Chai-AdisaksophaChatree}|DavidGomezAlmaguer{AlmaguerDavidGomez}|HuyTran{TranHuy}|Ho-JinShin{ShinHo-Jin}|MariaCristinaPascualIzquierdo{PascualIzquierdoMariaCristina}|IlyaKirgner{KirgnerIlya}|ElisaLucchini{LucchiniElisa}|GannaKuzmina{KuzminaGanna}|SylvainAudia{AudiaSylvain}|MatiasCordoba{CordobaMatias}|MeredithC.Foster{FosterMeredithC.}|MichelleLee{LeeMichelle}|AhmedDaak{DaakAhmed}|MeredithC,Foster{FosterMeredithC,}|ImeneGouia{GouiaImene}|MasakiIino{IinoMasaki}|YoshiakiTomiyama{TomiyamaYoshiaki}|HarumiKamiya{KamiyaHarumi}|JessicaZhang{ZhangJessica}|NinaSkuban{SkubanNina}|PriyankaSH{SHPriyanka}|AnugyaBhatt{BhattAnugya}|ManjuS{SManju}|LalitaNorasetthada{NorasetthadaLalita}|EkaratRattarittamrong{RattarittamrongEkarat}|ThanawatRattanathammethee{RattanathammetheeThanawat}|SasineeHantrakool{HantrakoolSasinee}|PokpongPiriyakhuntorn{PiriyakhuntornPokpong}|TeerachatPunnachet{PunnachetTeerachat}|SirichaiSrichairatanakool{SrichairatanakoolSirichai}|PiangraweeNiprapan{NiprapanPiangrawee}|AdisakTantiworawit{TantiworawitAdisak}|NurIlaydaGenc{GencNurIlayda}|SogolSadri{SadriSogol}|SinemCivrizBozdag{CivrizBozdagSinem}____Oral Session 1-14CPlatelet Disorder/Thrombosis____Rilzabrutinib in immune thrombocytopenia (ITP): Asian/Japanese sub-group analysis of Phase 3 study|Rilzabrutinib improved quality of life in immune thrombocytopenia: Phase 3 Asian sub-group analysis|One-year efficacy and safety of avatrombopag for chronic immune thrombocytopenia in Japanese adults|Blood component processing effect on platelet microparticles and evaluation as quality indicator|Prevalence of thrombosis and longitudinal clinical outcomes in Thai patients with polycythemia vera|Sunitinib-associated thrombotic microangiopathy: an unforeseen complication of TKI therapy

O1-14C

Oral Session 1-14C
Platelet Disorder/Thrombosis

Chair：Hirokazu Kashiwagi

ShigeharuOh{OhShigeharu}|YanisaBoonyayoi{BoonyayoiYanisa}|PeerapolManopak{ManopakPeerapol}|AndreeKurniawan{KurniawanAndree}|ChatreeChai-Adisaksopha{Chai-AdisaksophaChatree}____AkiraKatsumi{KatsumiAkira}____YutoNakajima{NakajimaYuto}|EisukeTakami{TakamiEisuke}|HirotoshiNakano{NakanoHirotoshi}|KeijiNogami{NogamiKeiji}|NatayaTeeyapun{TeeyapunNataya}|ChantiyaChanswangphuwana{ChanswangphuwanaChantiya}|PonlapatRojnuckarin{RojnuckarinPonlapat}|NoppacharnUaprasert{UaprasertNoppacharn}|ThitaChiasakul{ChiasakulThita}|PesolHankittikanchana{HankittikanchanaPesol}|ChanakritBoonplod{BoonplodChanakrit}|SaruttayaPrasatthum{PrasatthumSaruttaya}|PiangraweeNiprapan{NiprapanPiangrawee}|SupharaManowong{ManowongSuphara}|NuttanunWongsarikan{WongsarikanNuttanun}|ChatreeChai-Adisaksopha{Chai-AdisaksophaChatree}|RungroteNatesirinilkul{NatesirinilkulRungrote}|NatnitaMattawanon{MattawanonNatnita}|NonthakornHantrakun{HantrakunNonthakorn}|AngelineTancherla{TancherlaAngeline}|FernandoDharmaraja{DharmarajaFernando}|DeviAstriRiveraAmelia{AmeliaDeviAstriRivera}|ChandraSari{SariChandra}|DedenDjatnika{DjatnikaDeden}|DimasPriantono{PriantonoDimas}|NugrahenyPrasastiPurlikasari{PurlikasariNugrahenyPrasasti}|BetaAgustinWisman{WismanBetaAgustin}|FariedaAryanti{AryantiFarieda}|NiaNoviantiSiregar{SiregarNiaNovianti}|PhichayutPhinyo{PhinyoPhichayut}|WorakittiLapisatepun{LapisatepunWorakitti}|ChaiyutCharoentum{CharoentumChaiyut}|AdisakTantiworawit{TantiworawitAdisak}|EkaratRattarittamrong{RattarittamrongEkarat}|LalitaNorasetthada{NorasetthadaLalita}|PokpongPiriyakhuntorn{PiriyakhuntornPokpong}|ThanawatRattanathammethee{RattanathammetheeThanawat}|SasineeHantrakool{HantrakoolSasinee}|TeerachatPunnachet{PunnachetTeerachat}____Oral Session 1-14DCoagulation Disorder/Others____Factor X and factor VIIa/factor X augment coagulation potential in a TFPI-reduced hemophilia model|The clinical outcomes of venous thromboembolism in patients with hepatobiliary and pancreatic cancer|Impact of feminizing hormone therapy on coagulation and ROTEM parameters in transgender women|Association of antiphospholipid antibodies with the risk of thrombotic in lupus: a systematic review|Development and validation of a RAM for venous thromboembolism in patients with cholangiocarcinoma

O1-14D

Oral Session 1-14D
Coagulation Disorder/Others

Chair：Akira Katsumi

EmiYokoyama{YokoyamaEmi}|YusukeKamihara{KamiharaYusuke}|TaichiHatakeyama{HatakeyamaTaichi}|MasayaMorimoto{MorimotoMasaya}|Wan-ShiuanLin{LinWan-Shiuan}|ZongHanYao{YaoZongHan}____ShigeoFuji{FujiShigeo}____TaisukeHarada{HaradaTaisuke}|TomoyukiEndo{EndoTomoyuki}|HidekiGoto{GotoHideki}|JunichiSugita{SugitaJunichi}|MasayukiAiba{AibaMasayuki}|MutsumiTakahata{TakahataMutsumi}|TakutoMiyagishima{MiyagishimaTakuto}|HajimeSenjo{SenjoHajime}|SatoshiIyama{IyamaSatoshi}|ShuichiroTakahashi{TakahashiShuichiro}|MasayoYamamoto{YamamotoMasayo}|MotohiroShindo{ShindoMotohiro}|KazuyaSato{SatoKazuya}|JunichiHashiguchi{HashiguchiJunichi}|TatsuoOyake{OyakeTatsuo}|TakanoriTeshima{TeshimaTakanori}|TakumaFujihira{FujihiraTakuma}|RyusukeHoraguchi{HoraguchiRyusuke}|TomokiMinemura{MinemuraTomoki}|YoshimiNabe{NabeYoshimi}|KentoOno{OnoKento}|ShoheiKikuchi{KikuchiShohei}|AkinoriWada{WadaAkinori}|HiroyasuKaya{KayaHiroyasu}|HidekiTani{TaniHideki}|ShunsukeYazawa{YazawaShunsuke}|KazunoriOishi{OishiKazunori}|YoshitomoMorinaga{MorinagaYoshitomo}|TsutomuSato{SatoTsutomu}|AyaNishida{NishidaAya}|MikaKuno{KunoMika}|OtoyaWatanabe{WatanabeOtoya}|KyosukeYamaguchi{YamaguchiKyosuke}|KoseiKageyama{KageyamaKosei}|DaisukeKaji{KajiDaisuke}|YukiTaya{TayaYuki}|ShinsukeTakagi{TakagiShinsuke}|HisashiYamamoto{YamamotoHisashi}|ShoOgura{OguraSho}|HidekiAraoka{AraokaHideki}|AtsushiWake{WakeAtsushi}|GoYamamoto{YamamotoGo}|NaoyukiUchida{UchidaNaoyuki}|ShigekiNemoto{NemotoShigeki}|YukariInada{InadaYukari}|MitsutakaKimura{KimuraMitsutaka}|AiTsujita{TsujitaAi}|ToshikiMushino{MushinoToshiki}|ShogoMurata{MurataShogo}|HirokiHosoi{HosoiHiroki}|TakashiSonoki{SonokiTakashi}|YusukeKoizumi{KoizumiYusuke}|Yuan-HaoYang{YangYuan-Hao}|ShengkaiLiang{LiangShengkai}____Oral Session 1-15AInfections/Others____Progressive multifocal leukoencephalopathy based on hematological malignancies and HIV infection|Persistent COVID-19 during epcoritamab for DLBCL: potential role of immunoglobulin replacement|Retrospective study of 10 cases of disseminated trichosporonosis following allogeneic HSCT|Shift in daptomycin use for hematological malignancies: a single-center stewardship study|Hepatitis C virus and prognosis of hematologic malignancies: a propensity score matching analysis|Respiratory syncytial virus: a significant cause of respiratory failure in hematologic malignancies

O1-15A

Oral Session 1-15A
Infections/Others

Chair：Shigeo Fuji

KazuhideIizuka{IizukaKazuhide}|RyojiKobayashi{KobayashiRyoji}|FunaNorita{NoritaFuna}|NaokiUchida{UchidaNaoki}|TomoNakajima{NakajimaTomo}|FumiakiSano{SanoFumiaki}____YasuoMori{MoriYasuo}____HeihatirouOchiai{OchiaiHeihatirou}|YoshikazuIizuka{IizukaYoshikazu}|ShimonOotake{OotakeShimon}|YuichiTakeuchi{TakeuchiYuichi}|HironaoNukariya{NukariyaHironao}|HiromichiTakahashi{TakahashiHiromichi}|ShunIto{ItoShun}|TakashiHamada{HamadaTakashi}|NoriyoshiIriyama{IriyamaNoriyoshi}|YoshihiroHatta{HattaYoshihiro}|KatsuhiroMiura{MiuraKatsuhiro}|RyusukeIshigaki{IshigakiRyusuke}|SatoruMatsushima{MatsushimaSatoru}|DaikiHori{HoriDaiki}|MasatoYanagi{YanagiMasato}|HirozumiSano{SanoHirozumi}|DaisukeSuzuki{SuzukiDaisuke}|TomoakiAkagi{AkagiTomoaki}|ToruEbina{EbinaToru}|TakutoTachita{TachitaTakuto}|TakahikoFujii{FujiiTakahiko}|KohmeiKubo{KuboKohmei}|TomomiSuzaki{SuzakiTomomi}|ChisakoIriyama{IriyamaChisako}|AkinaoOkamoto{OkamotoAkinao}|HideyukiYamamoto{YamamotoHideyuki}|NaoeGoto{GotoNaoe}|KiyonobuTokuyama{TokuyamaKiyonobu}|ToshiharuKato{KatoToshiharu}|TaejoonKaneda{KanedaTaejoon}|KiichiShimizu{ShimizuKiichi}|TakahikoMiyama{MiyamaTakahiko}|TakanobuMorishita{MorishitaTakanobu}|MasatakaOkamoto{OkamotoMasataka}|KeikoHattori{HattoriKeiko}|MitsunagaIwata{IwataMitsunaga}|YoheiDoi{DoiYohei}|YoshihiroInamoto{InamotoYoshihiro}|AkihiroTomita{TomitaAkihiro}|TsubasaMiyagi{MiyagiTsubasa}|RikoMiyagi{MiyagiRiko}|SakikoKitamura{KitamuraSakiko}|KazuhoMorichika{MorichikaKazuho}|TakuyaFukushima{FukushimaTakuya}|HiroakiMasuzaki{MasuzakiHiroaki}|KumiOshima{OshimaKumi}|SanshiroUchida{UchidaSanshiro}|HayatoTamai{TamaiHayato}|MoekoSato{SatoMoeko}|ShintaroYoshihara{YoshiharaShintaro}|HirotakeWakamatsu{WakamatsuHirotake}|AyakoArai{AraiAyako}____Oral Session 1-15BBacterial/Viral Infections____Space disinfection using TiO2 photocatalyst reduces the incidence of febrile neutropenia (Final)|Detection of peri- and postmortem bacteria in patients with hematologic neoplastic diseases|Clinical features of CLABSI in patients received hematopoietic stem cell transplantation|Recent clinical features of SARS-CoV-2 infection in patients with hematological patients|Maribavir for CMV infection after allo-HSCT: a retrospective analysis of five cases|Comprehensive viral screening test after allo-HSCT using digital multiplex PCR

O1-15B

Oral Session 1-15B
Bacterial/Viral Infections

Chair：Yasuo Mori

HitomiSawa{SawaHitomi}|KeiichiAkizuki{AkizukiKeiichi}|OtoyaWatanabe{WatanabeOtoya}|GoichiYoshimoto{YoshimotoGoichi}|KoichiOhata{OhataKoichi}|MasashiSeki{SekiMasashi}____HirokiYokoyama{YokoyamaHiroki}____TakanoriMiura{MiuraTakanori}|MotoyasuKanazawa{KanazawaMotoyasu}|TaeNinomiya{NinomiyaTae}|NaoYoshida{YoshidaNao}|DaikiHarada{HaradaDaiki}|TaitoKiwada{KiwadaTaito}|SomiOzaki{OzakiSomi}|TomoyoshiWakayama{WakayamaTomoyoshi}|TomoyaArakawa{ArakawaTomoya}|HarukiKoketsu{KoketsuHaruki}|ToshiyasuSakai{SakaiToshiyasu}|KotaroMiyao{MiyaoKotaro}|YuichiroInagaki{InagakiYuichiro}|MasashiSawa{SawaMasashi}|KengoMatsumoto{MatsumotoKengo}|MasaakiSekine{SekineMasaaki}|AyakoKamiunten{KamiuntenAyako}|TakanoriToyama{ToyamaTakanori}|JunzoIshizaki{IshizakiJunzo}|KiyoshiYamashita{YamashitaKiyoshi}|KouichiMaeda{MaedaKouichi}|KoshiroNagamine{NagamineKoshiro}|RyomaIkeda{IkedaRyoma}|AyukaKuroki{KurokiAyuka}|MasayoshiKarasawa{KarasawaMasayoshi}|TakuroKameda{KamedaTakuro}|KotaroShide{ShideKotaro}|YokoKubuki{KubukiYoko}|KazuyaShimoda{ShimodaKazuya}|MikaKuno{KunoMika}|KyosukeYamaguchi{YamaguchiKyosuke}|KoseiKageyama{KageyamaKosei}|DaisukeKaji{KajiDaisuke}|YukiTaya{TayaYuki}|AyaNishida{NishidaAya}|KazuyaIshiwata{IshiwataKazuya}|ShinsukeTakagi{TakagiShinsuke}|HisashiYamamoto{YamamotoHisashi}|HidekiAraoka{AraokaHideki}|YukiMori{MoriYuki}|GoYamamoto{YamamotoGo}|AtsushiWake{WakeAtsushi}|NaoyukiUchida{UchidaNaoyuki}|HuiyeonChoi{ChoiHuiyeon}|MasatoIshimaru{IshimaruMasato}|ShintaroOga{OgaShintaro}|YuKochi{KochiYu}|TadafumiIino{IinoTadafumi}|NobuhiroKanemura{KanemuraNobuhiro}|RyoKobayashi{KobayashiRyo}|YutoKaneda{KanedaYuto}|YoshikazuIkoma{IkomaYoshikazu}|TakuroMatsumoto{MatsumotoTakuro}|NobuhikoNakamura{NakamuraNobuhiko}|HiroshiNakamura{NakamuraHiroshi}|YutoYamada{YamadaYuto}|TakashiNiwa{NiwaTakashi}|MioWada{WadaMio}|MomokoOhashi{OhashiMomoko}|MasahitoShimizu{ShimizuMasahito}|AkioSuzuki{SuzukiAkio}|NorihideSatoh{SatohNorihide}|SatoshiIsobe{IsobeSatoshi}|EijiSunami{SunamiEiji}|ShoheiMurata{MurataShohei}|JunjiShibahara{ShibaharaJunji}|NobuyukiTakayama{TakayamaNobuyuki}|ShunyaArai{AraiShunya}____Oral Session 1-15CFungal Infections____Factors influencing high plasma concentrations of VRCZ during the early phase of administration|Incidence and clinical characteristics of invasive fungal infections in patients receiving ibrutinib|Real-world experience with isavuconazole in a single center|The management of fungal infection using isavuconazole in patients with hematologic disorders|Real-world experience of isavuconazole in patients with hematological malignancies|Gastric mucormycosis during treatment for multiple myeloma: A case report

O1-15C

Oral Session 1-15C
Fungal Infections

Chair：Hiroki Yokoyama

MasahiroIeko{IekoMasahiro}|IbukiYasuda{YasudaIbuki}|AsukaSakata{SakataAsuka}|KeikoShinozawa{ShinozawaKeiko}|NaokiShinke{ShinkeNaoki}|HideoWada{WadaHideo}____MasakoNishikawa{NishikawaMasako}____SumiyoshiNaito{NaitoSumiyoshi}|KazumasaOhmura{OhmuraKazumasa}|MikaYoshida{YoshidaMika}|TerutoHashiguchi{HashiguchiTeruto}|HanaeSato{SatoHanae}|TomokiTogashi{TogashiTomoki}|SatomiNagaya{NagayaSatomi}|ErikoMorishita{MorishitaEriko}|KoheiTatsumi{TatsumiKohei}|NaokiMatsumoto{MatsumotoNaoki}|NigelMackman{MackmanNigel}|SuguruHarada{HaradaSuguru}|RyoheiKawasaki{KawasakiRyohei}|YukikoNishida{NishidaYukiko}|TetsuhiroSoeda{SoedaTetsuhiro}|KeijiNogami{NogamiKeiji}|MidoriShima{ShimaMidori}|MasatoBingo{BingoMasato}|AyanoMitsuhashi{MitsuhashiAyano}|YushiChikasawa{ChikasawaYushi}|HiroshiInaba{InabaHiroshi}|KagehiroAmano{AmanoKagehiro}|EiKinai{KinaiEi}|EriNakano{NakanoEri}|HideoWada{WadaHideo}|KatsuyaShiraki{ShirakiKatsuya}|TakeshiMatsumoto{MatsumotoTakeshi}|YukaSugimoto{SugimotoYuka}|KohshiOhishi{OhishiKohshi}|MasahiroMasuya{MasuyaMasahiro}|IsaoTawara{TawaraIsao}|HidetoShimpo{ShimpoHideto}|NaokiShinke{ShinkeNaoki}____Oral Session 1-15DThrombosis/Hemostasis: Others____Analysis of 24 cases of suspected autoimmune coagulation factor V deficiency|Molecular characterization of hereditary antithrombin deficiency type I due to NMD efficiency|The role of extravascular, platelet-independent coagulation in hemostasis after internal bleeding|The interpretation of gene variants with congenital fibrinogen disorders showing diverse phenotype|Analysis of hemostatic abnormalities in patients with polycythemia, thrombocytosis, and leukocytosis|Monitoring hemostasis to prevent thrombosis

O1-15D

Oral Session 1-15D
Thrombosis/Hemostasis: Others

Chair：Masako Nishikawa

ToshihideEndo{EndoToshihide}|RikiYamakawa{YamakawaRiki}|SouichiShiratori{ShiratoriSouichi}|NoriyoshiYoshinaga{YoshinagaNoriyoshi}|YayoiUeda{UedaYayoi}|KazukiYoshimura{YoshimuraKazuki}____DaigoHashimoto{HashimotoDaigo}____HiromichiTakahashi{TakahashiHiromichi}|TakahiroNamiki{NamikiTakahiro}|YoshiyukiHayashi{HayashiYoshiyuki}|ShunIto{ItoShun}|HironaoNukariya{NukariyaHironao}|KazuyaKurihara{KuriharaKazuya}|TakashiKoike{KoikeTakashi}|YuuichiTakeuchi{TakeuchiYuuichi}|TakashiHamada{HamadaTakashi}|ShimonOhtake{OhtakeShimon}|MasaruNakagawa{NakagawaMasaru}|KatsuhiroMiura{MiuraKatsuhiro}|HidekiNakamura{NakamuraHideki}|HiroakiShimizu{ShimizuHiroaki}|KairiKojo{KojoKairi}|KanaKato{KatoKana}|KaoriKondo{KondoKaori}|YasutakaSadaga{SadagaYasutaka}|RyoHasunuma{HasunumaRyo}|FumihikoOuchi{OuchiFumihiko}|AtsushiTakeyoshi{TakeyoshiAtsushi}|HirokiHatsusawa{HatsusawaHiroki}|MasashiShimabukuro{ShimabukuroMasashi}|AtsushiJinguji{JingujiAtsushi}|YukieTerasaki{TerasakiYukie}|DaichiSadato{SadatoDaichi}|ShuheiKurosawa{KurosawaShuhei}|KaoruMorita{MoritaKaoru}|YuhoNajima{NajimaYuho}|TomomiToubai{ToubaiTomomi}|YukaHarada{HaradaYuka}|KyokoHaraguchi{HaraguchiKyoko}|NorikoDoki{DokiNoriko}|KojiKato{KatoKoji}|ToshiroKawakita{KawakitaToshiro}|YasushiOnishi{OnishiYasushi}|Ken-ichiMatsuoka{MatsuokaKen-ichi}|KazuhiroIkegame{IkegameKazuhiro}|NobuhiroHiramoto{HiramotoNobuhiro}|MasakoToyosaki{ToyosakiMasako}|YutaKatayama{KatayamaYuta}|YuhkiKoga{KogaYuhki}|ShunMurayama{MurayamaShun}|YujiSasagawa{SasagawaYuji}|MamiShindo{ShindoMami}|KiyohikoHatake{HatakeKiyohiko}|YoshinobuMaeda{MaedaYoshinobu}|TakanoriTeshima{TeshimaTakanori}|YoshihiroInamoto{InamotoYoshihiro}|AsamiKataoka{KataokaAsami}|JunyaKanda{KandaJunya}|YasuyukiArai{AraiYasuyuki}|ToshioKitawaki{KitawakiToshio}|TakashiSakamoto{SakamotoTakashi}|KoheiYamashita{YamashitaKohei}|AkifumiTakaoriKondo{TakaoriKondoAkifumi}|HideakiFujiwara{FujiwaraHideaki}|DaisukeIkeda{IkedaDaisuke}|YusukeInoue{InoueYusuke}|TomohiroNagano{NaganoTomohiro}|RyuichiroHiyama{HiyamaRyuichiro}|YukiMizuno{MizunoYuki}|TakumiKondo{KondoTakumi}|KeisukeSeike{SeikeKeisuke}|NoboruAsada{AsadaNoboru}|DaisukeEnnishi{EnnishiDaisuke}|KeikoFujii{FujiiKeiko}|NobuharuFujii{FujiiNobuharu}|HidekiNakasone{NakasoneHideki}|JunkoTakeshita{TakeshitaJunko}|MasaharuTamaki{TamakiMasaharu}|SachikoSeo{SeoSachiko}|KunihkoTakahashi{TakahashiKunihko}|NaoyukiUchida{UchidaNaoyuki}|MasatsuguTanaka{TanakaMasatsugu}|TakahiroFukuda{FukudaTakahiro}|MasashiSawa{SawaMasashi}|JunIshikawa{IshikawaJun}|TetsuyaNishida{NishidaTetsuya}|MamikoSakata-Yanagimoto{Sakata-YanagimotoMamiko}|YutaHasegawa{HasegawaYuta}|ShinjiOnizuka{OnizukaShinji}|YoshinobuKanda{KandaYoshinobu}|YoshikoAtsuta{AtsutaYoshiko}|KimikazuYakushijin{YakushijinKimikazu}____Oral Session 1-16AHSCT: GVHD 1____Clinical significance of cytokine release syndrome in the early phase after HaploSCT by theQ-index|Impacts of CRS development on transplant outcomes in HLA-haploidentical transplantation with PTCy|Belumosudil in steroid-dependent/resistant cGVHD: Final results including post-marketing trial part|Efficacy of ibrutinib, ruxolitinib, and belumosudil in steroid-refractory chronic GVHD|The pulmonary complications after PTCy compared to non-PTCy|Comparison between COP and non-COP-IPS after hematopoietic cell transplantation

O1-16A

Oral Session 1-16A
HSCT: GVHD 1

Chair：Daigo Hashimoto

MakotoMurata{MurataMakoto}|MikaKuno{KunoMika}|KazuyaAsano{AsanoKazuya}|KenHashimoto{HashimotoKen}|TakumuTsuchida{TsuchidaTakumu}|ToruMiyajima{MiyajimaToru}____NorikoDoki{DokiNoriko}____SeitaroTerakura{TerakuraSeitaro}|JunyaKanda{KandaJunya}|NaoyukiUchida{UchidaNaoyuki}|SatoshiYoshihara{YoshiharaSatoshi}|TakahiroFukuda{FukudaTakahiro}|KeisukeKataoka{KataokaKeisuke}|KazuyaIshiwata{IshiwataKazuya}|NorikoDoki{DokiNoriko}|ShuichiOta{OtaShuichi}|MahoSato{SatoMaho}|MoekoHino{HinoMoeko}|MakotoOnizuka{OnizukaMakoto}|KenTabuchi{TabuchiKen}|YoshikoAtsuta{AtsutaYoshiko}|TakanoriTeshima{TeshimaTakanori}|HisashiYamamoto{YamamotoHisashi}|OtoyaWatanabe{WatanabeOtoya}|KyosukeYamaguchi{YamaguchiKyosuke}|KoseiKageyama{KageyamaKosei}|YukiTaya{TayaYuki}|DaisukeKaji{KajiDaisuke}|AyaNishida{NishidaAya}|ShinsukeTakagi{TakagiShinsuke}|YukiMori{MoriYuki}|GoYamamoto{YamamotoGo}|AtsushiWake{WakeAtsushi}|ShuichiTaniguchi{TaniguchiShuichi}|ShugoKowata{KowataShugo}|HarunaEchizenya{EchizenyaHaruna}|KentaroKobayashi{KobayashiKentaro}|RinoSugawara{SugawaraRino}|TsuyoshiSato{SatoTsuyoshi}|TakahiroMaeta{MaetaTakahiro}|MakiNishiya{NishiyaMaki}|YoshiakiOkano{OkanoYoshiaki}|SatsukiKamihara{KamiharaSatsuki}|TatsuoOyake{OyakeTatsuo}|ShigekiIto{ItoShigeki}|TakahikoSato{SatoTakahiko}|YuichiIshikawa{IshikawaYuichi}|YuichiroInagaki{InagakiYuichiro}|KotaroMiyao{MiyaoKotaro}|MasashiSawa{SawaMasashi}|TakanobuMorishita{MorishitaTakanobu}|TatsunoriGoto{GotoTatsunori}|TetsuyaNishida{NishidaTetsuya}|NobuakiFukushima{FukushimaNobuaki}|KazukiOzeki{OzekiKazuki}|DaisukeSugiyama{SugiyamaDaisuke}|RyoHanajiri{HanajiriRyo}|HitoshiKiyoi{KiyoiHitoshi}|TakashiUshiki{UshikiTakashi}|HajimeIshiguro{IshiguroHajime}|MihoYoshiike{YoshiikeMiho}|HikaruKanome{KanomeHikaru}|TatsuyaSuwabe{SuwabeTatsuya}|TakayukiKatagiri{KatagiriTakayuki}|KyokoFuse{FuseKyoko}|YasuhikoShibasaki{ShibasakiYasuhiko}|TakeroShindo{ShindoTakero}|KeiichiInoue{InoueKeiichi}|TomotakeKanki{KankiTomotake}|HirohitoSone{SoneHirohito}|MasayoshiMasuko{MasukoMasayoshi}|DaigoHashimoto{HashimotoDaigo}|AsakoMoriki{MorikiAsako}|KeisukeKojima{KojimaKeisuke}|ShihoriTsukamoto{TsukamotoShihori}|TomoeIchiki{IchikiTomoe}|YumikaSaito{SaitoYumika}|WenyuLi{LiWenyu}|ZixuanZhang{ZhangZixuan}|ShinpeiHarada{HaradaShinpei}|HajimeSenjo{SenjoHajime}|YukiYokoi{YokoiYuki}|YutaHasegawa{HasegawaYuta}|HiroyukiOhigashi{OhigashiHiroyuki}|TakahideAra{AraTakahide}|KiminoriNakamura{NakamuraKiminori}|KojiTaniguchi{TaniguchiKoji}____Oral Session 1-16BHSCT: GVHD 2____Comparison of mesenchymal stem cells and antithymocyte globulin as second-line acute GVHD therapy|Efficacy and safety of ruxolitinib in steroid-refractory acute GVHD after cord blood transplantation|The treatment response to acute GVHD is related to the proliferation and exhaustion of CD8 T-cells|CD56-expressing monocytes as a novel biomarker for acute graft-versus-host disease|NIX-mediated inhibition of mitophagy leads to activation and differentiation of T lymphocytes|GVHD-induced epigenetic imprinting promotes antigen presentation and apoptosis in IECs

O1-16B

Oral Session 1-16B
HSCT: GVHD 2

Chair：Noriko Doki

KojiKato{KatoKoji}|NorikoIwaki{IwakiNoriko}|SatsukiMurakami{MurakamiSatsuki}|KazutakaSuzuki{SuzukiKazutaka}|YuriMiyazawa{MiyazawaYuri}|RinoArita{AritaRino}____NaohiroSekiguchi{SekiguchiNaohiro}____DokHyunYoon{YoonDokHyun}|HyungwooCho{ChoHyungwoo}|TsuyoshiMuta{MutaTsuyoshi}|KenTakase{TakaseKen}|RyosukeOgawa{OgawaRyosuke}|MikaKuroiwa{KuroiwaMika}|YoshikiyoIto{ItoYoshikiyo}|TomohikoKamimura{KamimuraTomohiko}|KojiNagafuji{NagafujiKoji}|KazukiTanimoto{TanimotoKazuki}|TomoakiFujisaki{FujisakiTomoaki}|TetsuyaEto{EtoTetsuya}|NoriakiKawano{KawanoNoriaki}|NaokiHarada{HaradaNaoki}|KoichiAkashi{AkashiKoichi}|JasonYongshengChan{ChanJasonYongsheng}|HaiwenHuang{HuangHaiwen}|QingqingCai{CaiQingqing}|TongyuLin{LinTongyu}|UdomsakBunworasate{BunworasateUdomsak}|SenMuiTan{TanSenMui}|TsaiYunChen{ChenTsaiYun}|EstherChan{ChanEsther}|SooChinNg{NgSooChin}|NoorwatiSutandyo{SutandyoNoorwati}|HilmanTadjoedin{TadjoedinHilman}|AnnaMiraLubis{LubisAnnaMira}|DaJungKim{KimDaJung}|WonSeogKim{KimWonSeog}|KikuakiYoshida{YoshidaKikuaki}|NobuhikoYamauchi{YamauchiNobuhiko}|YusukeKoba{KobaYusuke}|YukoShirouchi{ShirouchiYuko}|YukoIshihara{IshiharaYuko}|YukoMishima{MishimaYuko}|ShinichiMakita{MakitaShinichi}|SuguruFukuhara{FukuharaSuguru}|WataruMunakata{MunakataWataru}|NorihitoInoue{InoueNorihito}|NaokoTsuyama{TsuyamaNaoko}|SenzoTaguchi{TaguchiSenzo}|TakashiTerauchi{TerauchiTakashi}|HidekiTsuji{TsujiHideki}|AkikoMaeshima{MaeshimaAkiko}|ShigenobuSuzuki{SuzukiShigenobu}|HiroshiIgaki{IgakiHiroshi}|KengoTakeuchi{TakeuchiKengo}|KojiIzutsu{IzutsuKoji}|DaiMaruyama{MaruyamaDai}|YasuhiroTakahashi{TakahashiYasuhiro}|KaoriUchino{UchinoKaori}|YukieSugita{SugitaYukie}|YuutoIsaji{IsajiYuuto}|SakuraSaigusa{SaigusaSakura}|YuusukeIida{IidaYuusuke}|SakiShinohara{ShinoharaSaki}|SaoriMatsumura{MatsumuraSaori}|TomohiroHorio{HorioTomohiro}|ShoheiMizuno{MizunoShohei}|KazuhiroIkegame{IkegameKazuhiro}|IchiroHanamura{HanamuraIchiro}|TaishiTakahara{TakaharaTaishi}|AkiraSato{SatoAkira}|YukihikoOoshima{OoshimaYukihiko}|AkiyoshiTakami{TakamiAkiyoshi}|KanaMiyazaki{MiyazakiKana}|NaokoAsano{AsanoNaoko}|HiroyukiTakahashi{TakahashiHiroyuki}|NobuhiroHiramoto{HiramotoNobuhiro}|IlseungChoi{ChoiIlseung}|HiroshiArima{ArimaHiroshi}|ToshikiUchida{UchidaToshiki}|HiroTatetsu{TatetsuHiro}|NobuhiroKanemura{KanemuraNobuhiro}|ShingoYano{YanoShingo}|ShunsukeIto{ItoShunsuke}|TakeharuKato{KatoTakeharu}|HirokazuSasaki{SasakiHirokazu}|TohruMurayama{MurayamaTohru}|JunjiHiraga{HiragaJunji}|NaokiTakahashi{TakahashiNaoki}|TetsuKobayashi{KobayashiTetsu}|MotoshiTakao{TakaoMotoshi}|IsaoTawara{TawaraIsao}|MotokoYamaguchi{YamaguchiMotoko}|AkihikoYokohama{YokohamaAkihiko}|IkukoMatsumura{MatsumuraIkuko}|HisashiTakei{TakeiHisashi}|NobuhikoKobayashi{KobayashiNobuhiko}|YoheiOsaki{OsakiYohei}|YoshiyukiOgawa{OgawaYoshiyuki}|TakayukiSaitoh{SaitohTakayuki}|HiroshiHanda{HandaHiroshi}|AyakoMuramatsu{MuramatsuAyako}|HarunoriSuzuki{SuzukiHarunori}|KoichiNonaka{NonakaKoichi}|MioSugitani{SugitaniMio}|TsutomuKobayashi{KobayashiTsutomu}|YosukeMatsumoto{MatsumotoYosuke}|ToshikiIwai{IwaiToshiki}|HitojiUchiyama{UchiyamaHitoji}____Oral Session 1-16CIndolent Lymphoma 1____Sequential BTK inhibitor therapy in relapsed/refractory mantle cell lymphoma|Clinical features and outcomes of localized ocular adnexal MALT lymphoma: a dual-center study|Clinical characteristics and treatment outcomes of ocular adnexal lymphoma: a retrospective study|Treatment and outcomes of pulmonary MALT lymphoma: a multi-institutional observational study|Efficacy, safety and cost-effectiveness of dexamethasone, rituximab, and cyclophosphamide for LPL/WM|Clinical characteristics and outcomes of Waldenstrom macroglobulinemia

O1-16C

Oral Session 1-16C
Indolent Lymphoma 1

Chair：Naohiro Sekiguchi

FuminariFujii{FujiiFuminari}|SatokoTogashi{TogashiSatoko}|HikaruKon{KonHikaru}|KosukeTakanashi{TakanashiKosuke}|TakeshiOkatani{OkataniTakeshi}|TadashiAbe{AbeTadashi}____ShunsukeHatta{HattaShunsuke}____DaisukeIkeda{IkedaDaisuke}|NaoyaFukuda{FukudaNaoya}|HajimeSakuma{SakumaHajime}|DaichiTerunuma{TerunumaDaichi}|KosukeShima{ShimaKosuke}|MasanoriToho{TohoMasanori}|AtsushiUehara{UeharaAtsushi}|RikakoTabata{TabataRikako}|MasamiTakeuchi{TakeuchiMasami}|KoseiMatsue{MatsueKosei}|YuYagi{YagiYu}|KahoFujino{FujinoKaho}|TakahitoKuga{KugaTakahito}|YusukeMasuda{MasudaYusuke}|KumikoFujita{FujitaKumiko}|NozomiKanai{KanaiNozomi}|KentoIshimine{IshimineKento}|TaroSawabe{SawabeTaro}|ManoMino{MinoMano}|AiTakahara{TakaharaAi}|TaichiTamura{TamuraTaichi}|ShoheiNakamura{NakamuraShohei}|ToshihiroOkuya{OkuyaToshihiro}|ShotaKusuhara{KusuharaShota}|ShinichiroMatsuda{MatsudaShinichiro}|YusukeKanemasa{KanemasaYusuke}|TatsuShimoyama{ShimoyamaTatsu}|EijiOgawa{OgawaEiji}|MizukiWatanabe{WatanabeMizuki}|HiroakiAbe{AbeHiroaki}|HikaruKumagai{KumagaiHikaru}|ToakiMaeda{MaedaToaki}|RyoNakagawa{NakagawaRyo}|AkihisaKawajiri{KawajiriAkihisa}|KyoukoInokura{InokuraKyouko}|KoichiOnodera{OnoderaKoichi}|ShunsukeHatta{HattaShunsuke}|NorikoFukuhara{FukuharaNoriko}|HideoHarigae{HarigaeHideo}|YurieMiyamoto{MiyamotoYurie}|YuiImai{ImaiYui}|HirohumiNakano{NakanoHirohumi}|MorihiroInoue{InoueMorihiro}|JunKato{KatoJun}|MasaoHagiwara{HagiwaraMasao}|TsuyoshiMuta{MutaTsuyoshi}|KoheiYamaguchi{YamaguchiKohei}|TakuyaNunomura{NunomuraTakuya}|TetsuroOchi{OchiTetsuro}|RyotaImanaka{ImanakaRyota}|SeiyaHirakawa{HirakawaSeiya}|KoheiKyo{KyoKohei}|MitsuhiroItagaki{ItagakiMitsuhiro}|ShinyaKatsutani{KatsutaniShinya}|MegumuFujihara{FujiharaMegumu}|HidekiAsaoku{AsaokuHideki}|YutaKatayama{KatayamaYuta}|TetsuzoTauchi{TauchiTetsuzo}|NobukoKubota{KubotaNobuko}|TetsuroNakazato{NakazatoTetsuro}|TsuyoshiSekizuka{SekizukaTsuyoshi}____Oral Session 1-16DIndolent Lymphoma 2____Prognosis prediction based on PETCT parameters and CD4+ T cell infiltration in follicular lymphoma|Real-world experience of rituximab and lenalidomide for relapsed or refractory indolent non-NHL|Bronchiolitis obliterans associated with B-cell lymphoma: a retrospective analysis of four cases|Efficacy and safety of tirabrutinib for Waldenstrom's macroglobulinemia: a single-center experience|Anthracycline, HD-AraC and Benda sequential chemotherapy in untreated MCL, a single institute data|Adverse events between rituximab biosimilar and reference rituximab: analysis of 140 cases

O1-16D

Oral Session 1-16D
Indolent Lymphoma 2

Chair：Shunsuke Hatta

ChikaTokuda{TokudaChika}|KairiKojo{KojoKairi}|ShunsukeNishino{NishinoShunsuke}|TatsuyaImi{ImiTatsuya}|KiwamuDoi{DoiKiwamu}|MihoOgawa{OgawaMiho}____ShinichiKako{KakoShinichi}____MakotoIwasaki{IwasakiMakoto}|JunyaKanda{KandaJunya}|TadakazuKondo{KondoTadakazu}|YasuyukiArai{AraiYasuyuki}|TakayukiIshikawa{IshikawaTakayuki}|KazunoriImada{ImadaKazunori}|YasunoriUeda{UedaYasunori}|AkihitoYonezawa{YonezawaAkihito}|KazuhiroYago{YagoKazuhiro}|TakashiIkeda{IkedaTakashi}|ToshiyukiKitano{KitanoToshiyuki}|TakashiAkasaka{AkasakaTakashi}|MasaharuNohgawa{NohgawaMasaharu}|MitsuruItoh{ItohMitsuru}|TomoharuTakeoka{TakeokaTomoharu}|NaoyukiAnzai{AnzaiNaoyuki}|NobuyoshiArima{ArimaNobuyoshi}|MasakatsuHishizawa{HishizawaMasakatsu}|MitsumasaWatanabe{WatanabeMitsumasa}|HirokazuHirata{HirataHirokazu}|KosukeAsagoe{AsagoeKosuke}|NoriyoshiYoshinaga{YoshinagaNoriyoshi}|TakashiSakamoto{SakamotoTakashi}|KouheiYamashita{YamashitaKouhei}|AkifumiTakaori{TakaoriAkifumi}|HiroakiShimizu{ShimizuHiroaki}|DaichiSadato{SadatoDaichi}|RikiYamakawa{YamakawaRiki}|KanaKato{KatoKana}|KaoriKondo{KondoKaori}|YasutakaSadaga{SadagaYasutaka}|AtsushiTakeyoshi{TakeyoshiAtsushi}|HirokiHatsusawa{HatsusawaHiroki}|YukieTerasaki{TerasakiYukie}|MasashiShimabukuro{ShimabukuroMasashi}|FumihikoOuchi{OuchiFumihiko}|AtsushiJinguji{JingujiAtsushi}|ShuheiKurosawa{KurosawaShuhei}|KaoruMorita{MoritaKaoru}|YuhoNajima{NajimaYuho}|TomomiToubai{ToubaiTomomi}|KyokoHaraguchi{HaraguchiKyoko}|YukaHarada{HaradaYuka}|NorikoDoki{DokiNoriko}|GoYamamoto{YamamotoGo}|HisashiYamamoto{YamamotoHisashi}|MikaKuno{KunoMika}|OtoyaWatanabe{WatanabeOtoya}|KyosukeYamaguchi{YamaguchiKyosuke}|KoseiKageyama{KageyamaKosei}|YukiTaya{TayaYuki}|DaisukeKaji{KajiDaisuke}|AyaNishida{NishidaAya}|ShinsukeTakagi{TakagiShinsuke}|YukiMori{MoriYuki}|NaoyukiUchida{UchidaNaoyuki}|YukioKondo{KondoYukio}|TakeharuKotani{KotaniTakeharu}|ToshiroKurokawa{KurokawaToshiro}|HideyukiTakamatsu{TakamatsuHideyuki}|AikoSawazaki{SawazakiAiko}|ShinyaYamada{YamadaShinya}|TakeshiYoroidaka{YoroidakaTakeshi}|YoshitakaZaimoku{ZaimokuYoshitaka}|HiroyukiMaruyama{MaruyamaHiroyuki}|AkiyoYoshida{YoshidaAkiyo}|HiroyukiTakamatsu{TakamatsuHiroyuki}|HirohitoYamazaki{YamazakiHirohito}|KoheiHosokawa{HosokawaKohei}|ToshihiroMiyamoto{MiyamotoToshihiro}|ChizukoHirama{HiramaChizuko}|KairiKojo{KojoKairi}|YasutakaMasuda{MasudaYasutaka}|YukiSakaida{SakaidaYuki}|ChikaKato{KatoChika}|RyoHasunuma{HasunumaRyo}|NaokiShingai{ShingaiNaoki}|TakashiToya{ToyaTakashi}|SyuheiKurosawa{KurosawaSyuhei}|YoshikiOkuyama{OkuyamaYoshiki}|HironoriHarada{HaradaHironori}|KazuakiYokoyama{YokoyamaKazuaki}|NozomiYusa{YusaNozomi}|MikaIto{ItoMika}|EigoShimizu{ShimizuEigo}|TakaakiKonuma{KonumaTakaaki}|SeikoKato{KatoSeiko}|SusumuTanoue{TanoueSusumu}|HirotoIshii{IshiiHiroto}|ShingoYano{YanoShingo}|TakayoshiTachibana{TachibanaTakayoshi}|ShokichiTsukamoto{TsukamotoShokichi}|EmikoSakaida{SakaidaEmiko}|NobuhiroTsukada{TsukadaNobuhiro}|YuheiNagao{NagaoYuhei}|AkihitoShinohara{ShinoharaAkihito}|ShinFujisawa{FujisawaShin}|TakuyaMiyazaki{MiyazakiTakuya}|TatsukiTomikawa{TomikawaTatsuki}|NobuyukiAotsuka{AotsukaNobuyuki}|MakotoOnizuka{OnizukaMakoto}|SatokoOsanai{OsanaiSatoko}|SeiyaImoto{ImotoSeiya}|YasuhitoNannya{NannyaYasuhito}|SatoshiTakahashi{TakahashiSatoshi}|YoshinobuKanda{KandaYoshinobu}____Oral Session 1-17AHSCT: Transplant Outcome 3____Significance of pretransplant and posttransplant MRD on survival outcomes in core-binding factor AML|Stratification of allo-HSCT outcomes in AML based on the ELN 2022 risk classification|Retrospective analysis of cord blood transplantation in patients with MDS and AML-MR|Outcomes of allogeneic hematopoietic stem cell transplantation for AML by donor type in Hokuriku|Outcomes after allo-HSCT in DDX41-mutated MDS/AML: A single-center retrospective study|Prognostic significance of residual circulating tumor-derived DNA post allo-HSCT in AML and MDS

O1-17A

Oral Session 1-17A
HSCT: Transplant Outcome 3

Chair：Shinichi Kako

MizukiWatanabe{WatanabeMizuki}|HiroyukiMuranushi{MuranushiHiroyuki}|AkihikoIzumi{IzumiAkihiko}|TomoyasuJo{JoTomoyasu}|KaiIshimaru{IshimaruKai}|YukiSakaida{SakaidaYuki}____MasayoshiMasuko{MasukoMasayoshi}____JunyaKanda{KandaJunya}|TakahiroFukuda{FukudaTakahiro}|KeitaroMatsuo{MatsuoKeitaro}|YuriIto{ItoYuri}|SungWongKim{KimSungWong}|ShinichiKako{KakoShinichi}|TatsuoIchinohe{IchinoheTatsuo}|YoshikoHashii{HashiiYoshiko}|HidekiGoto{GotoHideki}|KojiKato{KatoKoji}|MakotoYoshimitsu{YoshimitsuMakoto}|AtsumiYanagisawa{YanagisawaAtsumi}|MarieOhbiki{OhbikiMarie}|KenTabuchi{TabuchiKen}|YoshikoAtsuta{AtsutaYoshiko}|EiseiKondo{KondoEisei}|MasahitoTokunaga{TokunagaMasahito}|TetsuyaEto{EtoTetsuya}|YusukeHiguchi{HiguchiYusuke}|YasuhikoMiyazaki{MiyazakiYasuhiko}|KazunoriImada{ImadaKazunori}|YasuoMori{MoriYasuo}|YoshinobuKanda{KandaYoshinobu}|ShigeoFuji{FujiShigeo}|TakayoshiTachibana{TachibanaTakayoshi}|HirotoIshii{IshiiHiroto}|ShinichiroFujiwara{FujiwaraShinichiro}|YuhoNajima{NajimaYuho}|ChikakoOhwada{OhwadaChikako}|KotaYoshifuji{YoshifujiKota}|YutoHibino{HibinoYuto}|MasatsuguTanaka{TanakaMasatsugu}|ShunichiKimura{KimuraShunichi}|MasaharuTamaki{TamakiMasaharu}|ShingoYano{YanoShingo}|HirokiYokoyama{YokoyamaHiroki}|DaisukeMinakata{MinakataDaisuke}|ShokichiTsukamoto{TsukamotoShokichi}|EmikoSakaida{SakaidaEmiko}|NorikoDoki{DokiNoriko}|AkiraYokota{YokotaAkira}|TakuyaMiyazaki{MiyazakiTakuya}|NobuyukiAotsuka{AotsukaNobuyuki}|TadakazuKondo{KondoTadakazu}|ShoheiMizuno{MizunoShohei}|NaoyukiUchida{UchidaNaoyuki}|TetsuyaNishida{NishidaTetsuya}|MasashiSawa{SawaMasashi}|SatoruTakada{TakadaSatoru}|YutaHasegawa{HasegawaYuta}|KojiKawamura{KawamuraKoji}|MasamitsuYanada{YanadaMasamitsu}|YasuyukiArai{AraiYasuyuki}|ShinsukeTakagi{TakagiShinsuke}|MikaKuno{KunoMika}|OtoyaWatanabe{WatanabeOtoya}|DaisukeKaji{KajiDaisuke}|YukiTaya{TayaYuki}|AyaNishida{NishidaAya}|HisashiYamamoto{YamamotoHisashi}|YukiMori{MoriYuki}|GoYamamoto{YamamotoGo}|HiroakiShimizu{ShimizuHiroaki}|KaoruMorita{MoritaKaoru}|TomomiToubai{ToubaiTomomi}|AtsushiTakeyoshi{TakeyoshiAtsushi}|FumihikoOuchi{OuchiFumihiko}|HirokiHatsusawa{HatsusawaHiroki}|MasashiShimabukuro{ShimabukuroMasashi}|AtsushiJinguji{JingujiAtsushi}|YukieTerasaki{TerasakiYukie}|RyoHasunuma{HasunumaRyo}|ShuheiKurosawa{KurosawaShuhei}|KyokoHaraguchi{HaraguchiKyoko}|YukaHarada{HaradaYuka}____Oral Session 1-17BHSCT: Transplant Outcome 4____Impact of center-experience on transplant outcomes in adult patients with lymphomas|Comparison of peripheral blood and bone marrow in unrelated stem cell transplantation for ATL|Investigation of biomarkers in allogeneic transplantation for malignant lymphoma|Analyses of transplantation outcomes for adult patients with mixed-phenotype acute leukemia (MPAL)|Real-world outcomes of allo-HCT in mixed phenotype acute leukemia: A single-center study|Treatment outcomes of allogeneic stem cell transplantation for severe aplastic anemia

O1-17B

Oral Session 1-17B
HSCT: Transplant Outcome 4

Chair：Masayoshi Masuko

AmiInokuchi{InokuchiAmi}|KensukeMatsuda{MatsudaKensuke}|HitomiHosoya{HosoyaHitomi}|JenilJ.Doshi{DoshiJenilJ.}|PolinaKotselyabina{KotselyabinaPolina}|RaunakSingh{SinghRaunak}____AkinaoOkamoto{OkamotoAkinao}____HaryoonKim{KimHaryoon}|MasatoshiSakurai{SakuraiMasatoshi}|KyokoMasuda{MasudaKyoko}|KotaMizuno{MizunoKota}|YuyaKoda{KodaYuya}|EriMatsuki{MatsukiEri}|YasunoriKogure{KogureYasunori}|ShokoUkita{UkitaShoko}|MegumiMaeda{MaedaMegumi}|FutoshiOda{OdaFutoshi}|YasunoriSato{SatoYasunori}|HaruhisaFukuda{FukudaHaruhisa}|KeisukeKataoka{KataokaKeisuke}|RyoYoshimaru{YoshimaruRyo}|HirotakaNakamura{NakamuraHirotaka}|SungGiChi{ChiSungGi}|JunichiroYuda{YudaJunichiro}|SuguruFukuhara{FukuharaSuguru}|KojiIzutsu{IzutsuKoji}|YosukeMinami{MinamiYosuke}|ArmandoN.BastidasTorres{BastidasTorresArmandoN.}|SebastianFernandez-Pol{Fernandez-PolSebastian}|JohnGubatan{GubatanJohn}|SafaNajidh{NajidhSafa}|GeorgeDuran{DuranGeorge}|ZacharyE.Ehlinger{EhlingerZacharyE.}|ClaireLohman{LohmanClaire}|AlexaKwang{KwangAlexa}|CharlesWrightIII{WrightIIICharles}|DavidM.Kurtz{KurtzDavidM.}|BitaSahaf{SahafBita}|DavidB.Miklos{MiklosDavidB.}|SurbhiSidana{SidanaSurbhi}|LekhaMikkilineni{MikkilineniLekha}|MichaelKhodadoust{KhodadoustMichael}|AkashPawar{PawarAkash}|SangeetaKakoti{KakotiSangeeta}|NehalKhanna{KhannaNehal}|SiddharthaLaskar{LaskarSiddhartha}|JayantS.Goda{GodaJayantS.}|LiudmilaFedorova{FedorovaLiudmila}|KirillLepik{LepikKirill}|AnastasiaSemenova{SemenovaAnastasia}|ValeriaShpirko{ShpirkoValeria}|StanislavVolchenkov{VolchenkovStanislav}|IlyaZyuzgin{ZyuzginIlya}|GayaneTumyan{TumyanGayane}|NataliaMikhailova{MikhailovaNatalia}|AlexanderKulagin{KulaginAlexander}|AnkitaKanoja{KanojaAnkita}|UmaSakhdeo{SakhdeoUma}|OindrillaRoychowdhary{RoychowdharyOindrilla}|MeenakshiJeeva{JeevaMeenakshi}|EpariSridhar{SridharEpari}|HasmukhJain{JainHasmukh}|PriyaSingh{SinghPriya}|LingarajNaik{NaikLingaraj}|BhausahebBagal{BagalBhausaheb}____Oral Session 1-17CT/NK/HL: Genome Analysis and Real-world Data____Multiple medication use increases lymphoma risk in autoimmune diseases: Analysis from the LIFE Study|Clinical utility of NGS-based comprehensive genomic profiling in malignant lymphoma|Biclonal CAR T-cell lymphoma after ciltacabtagene autoleucel for relapsed multiple myeloma|Deep inspiration breath hold reduces cardiac and sub-cardiac radiation doses in mediastinal lymphoma|Non-transplant approach in second line in classical Hodgkin lymphoma: phase 2 trial (NCT05757466)|Real-world outcomes of advanced-stage nodular lymphocyte predominant Hodgkin lymphoma

O1-17C

Oral Session 1-17C
T/NK/HL: Genome Analysis and Real-world Data

Chair：Akinao Okamoto

KojiIzutsu{IzutsuKoji}|HiroshiYasui{YasuiHiroshi}|EijuNegoro{NegoroEiju}|SubaruWakisaka{WakisakaSubaru}|Tong-YaoXing{XingTong-Yao}|Jin-HuaLiang{LiangJin-Hua}____YasuhitoSuehara{SueharaYasuhito}____PierLuigiZinzani{ZinzaniPierLuigi}|NehaMehta-Shah{Mehta-ShahNeha}|EmmanuelBachy{BachyEmmanuel}|StefanBarta{BartaStefan}|ShigeruKusumoto{KusumotoShigeru}|MakotoYamagishi{YamagishiMakoto}|DavidKurtz{KurtzDavid}|YoshiyukiHizukuri{HizukuriYoshiyuki}|AngLi{LiAng}|TakayaMoriyama{MoriyamaTakaya}|LauraVersmee{VersmeeLaura}|KeikoNakajima{NakajimaKeiko}|StevenHorwitz{HorwitzSteven}|AikaFuseya{FuseyaAika}|MasahideYamamoto{YamamotoMasahide}|MiwakoNishio{NishioMiwako}|YuUemura{UemuraYu}|SubaruWakisaka{WakisakaSubaru}|KeisukeTanaka{TanakaKeisuke}|YoshihiroUmezawa{UmezawaYoshihiro}|KumiOshima{OshimaKumi}|HayatoTamai{TamaiHayato}|FumiakiSano{SanoFumiaki}|TakehikoMori{MoriTakehiko}|RyujiKoike{KoikeRyuji}|AyakoArai{AraiAyako}|TomoyukiSakai{SakaiTomoyuki}|ShoheiKikuchi{KikuchiShohei}|TsutomuSato{SatoTsutomu}|YasufumiMasaki{MasakiYasufumi}|TakahiroYamauchi{YamauchiTakahiro}|RyoKitabayashi{KitabayashiRyo}|HiroshiYasui{YasuiHiroshi}|AkihiroHirakawa{HirakawaAkihiro}|Jin-HuaLiang{LiangJin-Hua}|Wei-TingWang{WangWei-Ting}|LiWang{WangLi}|Jian-YongLi{LiJian-Yong}|WeiXu{XuWei}|Zi-WenDuan{DuanZi-Wen}|Tong-YaoXing{XingTong-Yao}____Oral Session 1-17DT/NK/HL: Clinical Trials and Disease Analysis____The correlation of mutational profiles and efficacy in Pts with R/R PTCL: VALENTINE-PTCL01 Trial|Significance of ALT and ferritin levels in defining distinct disease subtypes in CAEBV|Darinaparsin in patient with R/R PTCL: DARTS single agent multicenter observational study|Prognostic impact of EBV-DNA levels in peripheral blood mononuclear cells in CAEBV|The prognostic value of circulating cell-free methylated EBV-DNA in extranodal NK/T cell lymphoma|ABBV-CLS-484 disrupts mitochondrial renewal and mitophagy to exert anti-tumor activities in ALK+ALCL

O1-17D

Oral Session 1-17D
T/NK/HL: Clinical Trials and Disease Analysis

Chair：Yasuhito Suehara

NaotoTakahashi{TakahashiNaoto}|KotaroMiyao{MiyaoKotaro}|TakashiAbe{AbeTakashi}|SatoshiNishiwaki{NishiwakiSatoshi}|KengoMatsumoto{MatsumotoKengo}|TomohiroTaya{TayaTomohiro}____MakotoOnizuka{OnizukaMakoto}____YoshiakiYanai{YanaiYoshiaki}|YoshiyukiShibasaki{ShibasakiYoshiyuki}|TsunekoMizuno{MizunoTsuneko}|NorihiroNakamichi{NakamichiNorihiro}|ToshiyasuSakai{SakaiToshiyasu}|MotoyasuKanazawa{KanazawaMotoyasu}|TaeNinomiya{NinomiyaTae}|NaoYoshida{YoshidaNao}|DaikiHarada{HaradaDaiki}|TaitoKiwada{KiwadaTaito}|SomiOzaki{OzakiSomi}|TomoyoshiWakayama{WakayamaTomoyoshi}|TomoyaArakawa{ArakawaTomoya}|HarukiKoketsu{KoketsuHaruki}|HitomiSawa{SawaHitomi}|YuichiroInagaki{InagakiYuichiro}|MasashiSawa{SawaMasashi}|IsamuSugiura{SugiuraIsamu}|ShinFujisawa{FujisawaShin}|YoshihiroHatta{HattaYoshihiro}|YoshikoAtsuta{AtsutaYoshiko}|NorikoDoki{DokiNoriko}|ShingoKurahashi{KurahashiShingo}|YasunoriUeda{UedaYasunori}|NobuakiDobashi{DobashiNobuaki}|TomoyaMaeda{MaedaTomoya}|ItaruMatsumura{MatsumuraItaru}|MasatsuguTanaka{TanakaMasatsugu}|ShinichiKako{KakoShinichi}|TatsuoIchinohe{IchinoheTatsuo}|TakahiroFukuda{FukudaTakahiro}|ShigekiOhtake{OhtakeShigeki}|YuichiIshikawa{IshikawaYuichi}|YasushiMiyazaki{MiyazakiYasushi}|HitoshiKiyoi{KiyoiHitoshi}|AyukaKuroki{KurokiAyuka}|KoshiroNagamine{NagamineKoshiro}|RyomaIkeda{IkedaRyoma}|YukiTahira{TahiraYuki}|KeiichiAkizuki{AkizukiKeiichi}|AyakoKamiunten{KamiuntenAyako}|TakuroKameda{KamedaTakuro}|KotaroShide{ShideKotaro}|YokoKubuki{KubukiYoko}|KazuyaShimoda{ShimodaKazuya}|TakaoIshii{IshiiTakao}|SeiichiSato{SatoSeiichi}|KouichiMaeda{MaedaKouichi}|TomoyasuJo{JoTomoyasu}|YasuyukiArai{AraiYasuyuki}|TadakazuKondo{KondoTadakazu}|JunyaKanda{KandaJunya}|FumiyaWada{WadaFumiya}|TakeshiMaeda{MaedaTakeshi}|KazunoriImada{ImadaKazunori}|TakashiAkasaka{AkasakaTakashi}|AkihitoYonezawa{YonezawaAkihito}|TakashiIkeda{IkedaTakashi}|KazuhiroYago{YagoKazuhiro}|MasaakiTsuji{TsujiMasaaki}|ToshiyukiKitano{KitanoToshiyuki}|MitsuruItoh{ItohMitsuru}|SatokoOka{OkaSatoko}|YoshitomoMaesako{MaesakoYoshitomo}|HirokoTsunemine{TsunemineHiroko}|MasakatsuHishizawa{HishizawaMasakatsu}|NaokoHiranuma{HiranumaNaoko}|MitsumasaWatanabe{WatanabeMitsumasa}|AkifumiTakaoriKondo{TakaoriKondoAkifumi}____Oral Session 1-18APh+ ALL____Real-world study investigating survival in Japanese adult patient with Ph+ALL treated with ponatinib|Concurrent ponatinib and blinatumomab in adult Philadelphia chromosome-positive ALL|The potential for TFR in Ph (+) ALL by long-term maintenance therapy with ponatinib|Dasatinib vs. imatinib in adult Ph+ ALL: a pooled analysis of JALSG prospective trials|Single center analysis of treatment outcomes in elderly patients with Ph +ALL|Pre-transplant TKI choice does not influence prognosis in Ph+ ALL

O1-18A

Oral Session 1-18A
Ph+ ALL

Chair：Makoto Onizuka

TakashiMikami{MikamiTakashi}|KanaKato{KatoKana}|HisashiIshida{IshidaHisashi}|ShinKasai{KasaiShin}|HayatoTamai{TamaiHayato}|DaichiSadato{SadatoDaichi}____MasatsuguTanaka{TanakaMasatsugu}____ItaruKato{KatoItaru}|HidefumiHiramatsu{HiramatsuHidefumi}|YoshinoriUchihara{UchiharaYoshinori}|TakayaMitsuyoshi{MitsuyoshiTakaya}|ToshioKitawaki{KitawakiToshio}|SatoshiSaida{SaidaSatoshi}|KatsutsuguUmeda{UmedaKatsutsugu}|SeishiOgawa{OgawaSeishi}|AkifumiTakaoriKondo{TakaoriKondoAkifumi}|JamesWingBadger{WingBadgerJames}|JunkoTakita{TakitaJunko}|TakashiToya{ToyaTakashi}|DaichiSadato{SadatoDaichi}|ChizukoHirama{HiramaChizuko}|KairiKojo{KojoKairi}|RikiYamakawa{YamakawaRiki}|KaoriKondo{KondoKaori}|YasutakaSadaga{SadagaYasutaka}|ChikaKato{KatoChika}|SatoshiSakai{SakaiSatoshi}|FumihikoOuchi{OuchiFumihiko}|MasashiShimabukuro{ShimabukuroMasashi}|KazukiInai{InaiKazuki}|AtsushiJinguji{JingujiAtsushi}|NaokiShingai{ShingaiNaoki}|KaoruMorita{MoritaKaoru}|HiroakiShimizu{ShimizuHiroaki}|YuhoNajima{NajimaYuho}|TakeshiKobayashi{KobayashiTakeshi}|TomomiToubai{ToubaiTomomi}|HironoriHarada{HaradaHironori}|YukaHarada{HaradaYuka}|NorikoDoki{DokiNoriko}|YasuhiroOkamoto{OkamotoYasuhiro}|HirotoshiSakaguchi{SakaguchiHirotoshi}|YasuyukiArai{AraiYasuyuki}|TomoakiUeda{UedaTomoaki}|ShunsukeYamamoto{YamamotoShunsuke}|MioYano{YanoMio}|TomokoYokosuka{YokosukaTomoko}|KeikoOkada{OkadaKeiko}|MahoSato{SatoMaho}|ShuheiKarakawa{KarakawaShuhei}|YuhkiKoga{KogaYuhki}|NaoYoshida{YoshidaNao}|AtsushiSato{SatoAtsushi}|MoekoHino{HinoMoeko}|KenTabuchi{TabuchiKen}|YukiArakawa{ArakawaYuki}|KoshiAkahane{AkahaneKoshi}|MinoriTamai{TamaiMinori}|ThaoTTNguyen{NguyenThaoTT}|NobutakaKiyokawa{KiyokawaNobutaka}|HiroakiGoto{GotoHiroaki}|MasayoshiMinegishi{MinegishiMasayoshi}|ToshiyaInaba{InabaToshiya}|ShotaroIwamoto{IwamotoShotaro}|ChiakiKomatsu{KomatsuChiaki}|KeikoKagami{KagamiKeiko}|YukihiroSugita{SugitaYukihiro}|HirokoOshiro{OshiroHiroko}|KumikoGoi{GoiKumiko}|TakeshiInukai{InukaiTakeshi}|KoichiMiyake{MiyakeKoichi}|NorikoMiiyake{MiiyakeNoriko}|JunkoAsano{AsanoJunko}|AyakoArai{AraiAyako}|HirokoKogure{KogureHiroko}|SonomiTakakuwa{TakakuwaSonomi}|YuArikawa{ArikawaYu}____Oral Session 1-18BALL: Transplant & Novel Therapy____Tisa-cel efficacy for ALL is predicted by T cell phenotype and ADO productivity via CD38-CD73 axis|A classification system for transplant outcomes based on clinical and genetic features of ALL|Transplantation outcome for acute lymphoblastic leukemia in children with Down syndrome|Significance of BCL2 expression and TP53 mutation in sensitivity to inotuzumab ozogamicin in BCP-ALL|Preclinical efficacy of amlexanox - Ara-C in ALL with KMT2A::AFF1|Clinical utility of freeze-preserved bone marrow biopsies for targeted sequencing

O1-18B

Oral Session 1-18B
ALL: Transplant & Novel Therapy

Chair：Masatsugu Tanaka

PKEpling-Burnette{Epling-BurnettePK}|QuCui{CuiQu}|ArchitGoel{GoelArchit}|YuedanChen{ChenYuedan}|ShoheiKikuchi{KikuchiShohei}|ShukukoMiyakoshi{MiyakoshiShukuko}____HiroyukiTakahashi{TakahashiHiroyuki}____GregoryP.Takacs{TakacsGregoryP.}|ValerieRobinson{RobinsonValerie}|DavidAndorsky{AndorskyDavid}|RakheeVaidya{VaidyaRakhee}|AdelbaL.TorresLopez{TorresLopezAdelbaL.}|DavidSharon{SharonDavid}|KojoOsei-Bonsu{Osei-BonsuKojo}|KristinA.Conte{ConteKristinA.}|AndrewJ.Steele{SteeleAndrewJ.}|MartinaSeiffert{SeiffertMartina}|EdithSzafer-Glusman{Szafer-GlusmanEdith}|NehaDixit{DixitNeha}|RuixianXing{XingRuixian}|HuixiuHan{HanHuixiu}|XueyanBai{BaiXueyan}|JunQian{QianJun}|XueyanSun{SunXueyan}|ShingenNakamura{NakamuraShingen}|LinFu{FuLin}|TathagataJha{JhaTathagata}|SiddhantGovekar{GovekarSiddhant}|SambitKumarPradhan{PradhanSambitKumar}|GargiKapatia{KapatiaGargi}|AkhileshPathak{PathakAkhilesh}|VinaySuresh{SureshVinay}|QuCui{CuiQu}|WenyuanLai{LaiWenyuan}|YuchenWu{WuYuchen}|JingLiu{LiuJing}|QingLiu{LiuQing}|XuefeiSun{SunXuefei}|EijuNegoro{NegoroEiju}|YusukeKamihara{KamiharaYusuke}|AkinoriWada{WadaAkinori}|YasufumiMasaki{MasakiYasufumi}|ToshihiroMiyamoto{MiyamotoToshihiro}|TakahiroYamauchi{YamauchiTakahiro}|TsutomuSato{SatoTsutomu}|TakumuTsuchida{TsuchidaTakumu}|RuiTakeda{TakedaRui}|ChiakiFujino{FujinoChiaki}|SadaoAoki{AokiSadao}____Oral Session 1-18CDLBCL: Bispecific Antibody/PCNSL/Others____CD3xCD20 bispecific epcoritamab induces antitumor activity and favorable T-cell dynamics over time|Glofitamab plus selinexor as salvage therapy for relapsed primary central nervous system lymphoma|Efficacy of pharmacological and radiotherapy options in primary CNS lymphoma: a network meta analysis|Preliminary exploration of R-MIAD in the treatment of newly diagnosed PCNSL|Denosumab for steroid-induced osteoporosis in malignant lymphoma: a multicenter phase III study|Evaluation of the efficacy and safety of Pola-R-CHP in elderly patients with DLBCL

O1-18C

Oral Session 1-18C
DLBCL: Bispecific Antibody/PCNSL/Others

Chair：Hiroyuki Takahashi

MinoruKanaya{KanayaMinoru}|RikakoTabata{TabataRikako}|YasunobuSekiguchi{SekiguchiYasunobu}|HidekiGoto{GotoHideki}|SuguruFukuhara{FukuharaSuguru}|DaiMaruyama{MaruyamaDai}____SuguruFukuhara{FukuharaSuguru}____AkinaoOkamoto{OkamotoAkinao}|HidekiGoto{GotoHideki}|ReikiOgasawara{OgasawaraReiki}|KoseiMatsue{MatsueKosei}|KoEbata{EbataKo}|EmiYokoyama{YokoyamaEmi}|SatoshiYamamoto{YamamotoSatoshi}|HajimeSenjo{SenjoHajime}|TomoyukiSaga{SagaTomoyuki}|JunichiHashiguchi{HashiguchiJunichi}|MasayoYamamoto{YamamotoMasayo}|KaoriUchino{UchinoKaori}|MasahiroChiba{ChibaMasahiro}|MutsumiTakahata{TakahataMutsumi}|TetsuyukiIgarashi{IgarashiTetsuyuki}|YutoMori{MoriYuto}|KeitoYokoyama{YokoyamaKeito}|KeitoSuto{SutoKeito}|MasaoNakagawa{NakagawaMasao}|AkihiroTomita{TomitaAkihiro}|TakanoriTeshima{TeshimaTakanori}|NaoyaFukuda{FukudaNaoya}|HajimeSakuma{SakumaHajime}|KosukeShima{ShimaKosuke}|DaichiTerunuma{TerunumaDaichi}|FuminariFujii{FujiiFuminari}|MasanoriToho{TohoMasanori}|AtsushiUehara{UeharaAtsushi}|KentaroNarita{NaritaKentaro}|MasamiTakeuchi{TakeuchiMasami}|ShizukaHamano{HamanoShizuka}|KousukeArai{AraiKousuke}|HirokiTsutsumi{TsutsumiHiroki}|MasahisaKudo{KudoMasahisa}|NobuoMaseki{MasekiNobuo}|YoshieIizaki{IizakiYoshie}|MachikoKawamura{KawamuraMachiko}|KazuhikoKobayashi{KobayashiKazuhiko}|YuNishimura{NishimuraYu}|HiroakiKanda{KandaHiroaki}|DaisukeTakei{TakeiDaisuke}|TomoyaAbe{AbeTomoya}|MakotoHanai{HanaiMakoto}|ToshiakiNakayama{NakayamaToshiaki}|SayakaEndo{EndoSayaka}|YuKakusaka{KakusakaYu}|YasumasaShimano{ShimanoYasumasa}|HirofumiKobayashi{KobayashiHirofumi}|TakahiroKumode{KumodeTakahiro}|KeikoAizawa{AizawaKeiko}|NorikoFukuhara{FukuharaNoriko}|KojiKato{KatoKoji}|JasonR.Westin{R.WestinJason}|WonSeogKim{KimWonSeog}|ChiemiMori{MoriChiemi}|TatsukiImaizumi{ImaizumiTatsuki}|DaiMaruyama{MaruyamaDai}|ShinichiMakita{MakitaShinichi}|YukoShirouchi{ShirouchiYuko}|YukoMishima{MishimaYuko}|YasuhitoTerui{TeruiYasuhito}|TakuroSuzuki{SuzukiTakuro}|AtsukoKawasaki{KawasakiAtsuko}|TakeshiMiyake{MiyakeTakeshi}|KojiIzutsu{IzutsuKoji}|MasahiroTakeuchi{TakeuchiMasahiro}|KatsuyaFujimoto{FujimotoKatsuya}|KazutakaSunami{SunamiKazutaka}|RikaSakai{SakaiRika}|ToshiroKawakita{KawakitaToshiro}|EijuNegoro{NegoroEiju}|JunichiroYuda{YudaJunichiro}|KentaroFukushima{FukushimaKentaro}|ToshikiUchida{UchidaToshiki}|YuyaNagai{NagaiYuya}|KanaMiyazaki{MiyazakiKana}|IsaoYoshida{YoshidaIsao}|KenzoKinami{KinamiKenzo}|YiCui{CuiYi}|KazumiSuzukawa{SuzukawaKazumi}|YoukoSuehiro{SuehiroYouko}____Oral Session 1-18DAggressive B-cell Lymphoma: Antibody Therapy____Interim analysis of the NJHSG-Epcoritamab 2024 for relapsed/refractory LBCL|Characteristics linked to response to epcoritamab in refractory DLBCL and FL|Experience with the use of epcoritamab in a real-world setting in 18 patients at our institute|Efficacy and safety of mosunetuzumab (SC) + polatuzumab vedotin for Japanese patients with R/R LBCL|Phase I study of glofitamab in Japanese patients with relapsed/refractory non-Hodgkin lymphoma (NHL)|Tafasitamab plus lenalidomide in Japanese patients with R/R DLBCL: J-MIND Phase 2 primary analysis

O1-18D

Oral Session 1-18D
Aggressive B-cell Lymphoma: Antibody Therapy

Chair：Suguru Fukuhara

ShigekiIto{ItoShigeki}|AjaiChari{ChariAjai}|LingZhong{ZhongLing}|ShokichiTsukamoto{TsukamotoShokichi}|NoriyoshiIriyama{IriyamaNoriyoshi}|ItaruNishikawa{NishikawaItaru}____HiroshiHanda{HandaHiroshi}____YoshiakiKuroda{KurodaYoshiaki}|KazutakaSunami{SunamiKazutaka}|KoseiMatsue{MatsueKosei}|KazunoriImada{ImadaKazunori}|HidetoTamura{TamuraHideto}|ManamiTakizawa{TakizawaManami}|MarimoTakahashi{TakahashiMarimo}|MikihiroTakamoto{TakamotoMikihiro}|HiroshiHorio{HorioHiroshi}|LixiaPei{PeiLixia}|XiangQin{QinXiang}|TaraJ.Masterson{MastersonTaraJ.}|MichelaCampagna{CampagnaMichela}|VeroniqueVreys{VreysVeronique}|BonnieW.Lau{LauBonnieW.}|YusukeIzumi{IzumiYusuke}|YasushiTakamatsu{TakamatsuYasushi}|CarolinaSchinke{SchinkeCarolina}|CyrilleTouzeau{TouzeauCyrille}|MoniqueC.Minnema{MinnemaMoniqueC.}|NielsWCJvandeDonk{vandeDonkNielsWCJ}|PaulaRodriguez-Otero{Rodriguez-OteroPaula}|Maria-VictoriaMateos{MateosMaria-Victoria}|JingChristineYe{YeJingChristine}|ChalmerTomlinson{TomlinsonChalmer}|DeekshaVishwamitra{VishwamitraDeeksha}|IndrajeetSingh{SinghIndrajeet}|TaraMasterson{MastersonTara}|ThomasRenaud{RenaudThomas}|ChristophHeuck{HeuckChristoph}|LeoRasche{RascheLeo}|ChunbaoXie{XieChunbao}|JiLuo{LuoJi}|YingmiaoWu{WuYingmiao}|YajieWu{WuYajie}|YusukeTakeda{TakedaYusuke}|ChihiroHamada{HamadaChihiro}|AyakaNishihara{NishiharaAyaka}|ShintaroIzumi{IzumiShintaro}|ShinichiroMatsui{MatsuiShinichiro}|ArataIshii{IshiiArata}|NagisaOshima{OshimaNagisa}|YuheiNagao{NagaoYuhei}|KatsuhiroShono{ShonoKatsuhiro}|MasahiroOnoda{OnodaMasahiro}|AkiraYokota{YokotaAkira}|ShinichiMasuda{MasudaShinichi}|NobuyukiAotsuka{AotsukaNobuyuki}|KentaroNarita{NaritaKentaro}|MasamiTakeuchi{TakeuchiMasami}|NaoyaMimura{MimuraNaoya}|EmikoSakaida{SakaidaEmiko}|HitomiNakayama{NakayamaHitomi}|MasaruNakagawa{NakagawaMasaru}|AtsushiTakahata{TakahataAtsushi}|ErikoSato{SatoEriko}|MotokiTakano{TakanoMotoki}|KeigoOkada{OkadaKeigo}|KohtaroToyama{ToyamaKohtaro}|ToshiakiHayashi{HayashiToshiaki}|TakashiAbe{AbeTakashi}|KeisukeTanaka{TanakaKeisuke}|YasuhikoSenpuku{SenpukuYasuhiko}|YukiOsada{OsadaYuki}|JunichiWatanabe{WatanabeJunichi}|AkiraYamamoto{YamamotoAkira}|YasunobuSekiguchi{SekiguchiYasunobu}|GakuOshikawa{OshikawaGaku}|YutaKimura{KimuraYuta}|MichihideTokuhira{TokuhiraMichihide}|KenSuzuki{SuzukiKen}|TakashiKumagai{KumagaiTakashi}|TakayukiIkezoe{IkezoeTakayuki}|ShigeoToyota{ToyotaShigeo}|KatsuhiroMiura{MiuraKatsuhiro}|TomonoriNakazato{NakazatoTomonori}|TakehikoMori{MoriTakehiko}|TatsuyaImi{ImiTatsuya}|KokiOnishi{OnishiKoki}|YusukeNakata{NakataYusuke}|MasatakaSakashita{SakashitaMasataka}|HirokiYoshino{YoshinoHiroki}|ShinyaYamada{YamadaShinya}|TakeshiYoroidaka{YoroidakaTakeshi}|HirokiMizumaki{MizumakiHiroki}|HiroyukiMaruyama{MaruyamaHiroyuki}|AkiyoYoshida{YoshidaAkiyo}|HiroyukiTakamatsu{TakamatsuHiroyuki}|KoheiHosokawa{HosokawaKohei}|ToshihiroMiyamoto{MiyamotoToshihiro}____Oral Session 1-19AClinical Trials in Multiple Myeloma 1____Talquetamab in Japanese patients with relapsed/refractory MM: results from Phase 2 of MonumenTAL-1|Talquetamab, a GPRC5D×CD3 bispecific antibody, in RRMM: long-term results from MonumenTAL-1|Exome and transcriptome sequencing reveal prognostic mutation genes in Chinese MM|Elotuzumab/lenalidomide maintenance after autologous stem cell transplantation in multiple myeloma|Favorable response to daratumumab-combined therapy in MM patients with immature phenotype|The efficacy of daratumumab-based therapy for AL amyloidosis

O1-19A

Oral Session 1-19A
Clinical Trials in Multiple Myeloma 1

Chair：Hiroshi Handa

KazuhitoSuzuki{SuzukiKazuhito}|HirotoKojima{KojimaHiroto}|TomoakiFujisaki{FujisakiTomoaki}|ShinsukeIida{IidaShinsuke}____ShigekiIto{ItoShigeki}____SuzanneTrudel{TrudelSuzanne}|MeralBeksac{BeksacMeral}|LudekPour{PourLudek}|SosanaDelimpasi{DelimpasiSosana}|HangQuach{QuachHang}|VladimirVorobyev{VorobyevVladimir}|MicheleCavo{CavoMichele}|PawelRobak{RobakPawel}|KristinMorris{MorrisKristin}|CheePaulLin{LinCheePaul}|IanireGarrobo-Calleja{Garrobo-CallejaIanire}|GiuliaFulci{FulciGiulia}|ElisabetE.Manasanch{ManasanchElisabetE.}|BrandonE.Kremer{KremerBrandonE.}|María-VictoriaMateos{MateosMaría-Victoria}|MeletiosA.Dimopoulos{DimopoulosMeletiosA.}|RomanHajek{HajekRoman}|MeletiosAthanasiosDimopoulos{DimopoulosMeletiosAthanasios}|VaniaHungria{HungriaVania}|MarekHus{HusMarek}|KihyunKim{KimKihyun}|VeraZherebtsova{ZherebtsovaVera}|SergeyVoloshin{VoloshinSergey}|EstherGonzalezGarcia{GarciaEstherGonzalez}|HanlonSia{SiaHanlon}|Chang-KiMin{MinChang-Ki}|MarceloPitombeiradeLacerda{PitombeiradeLacerdaMarcelo}|AnnaMariaSuredaBalari{SuredaBalariAnnaMaria}|IvanSpicka{SpickaIvan}|ChristopherWard{WardChristopher}|PhoebeJoyHo{HoPhoebeJoy}|AnaCarolinaRibasdeAlmeida{RibasdeAlmeidaAnaCarolina}|SebastianGrosicki{GrosickiSebastian}|EricLewis{LewisEric}|JulieByrne{ByrneJulie}|BengaKazeem{KazeemBenga}|HenaBaig{BaigHena}|NickPirooz{PiroozNick}|SybilVarghese{VargheseSybil}|JoeLee{LeeJoe}|AdamBryant{BryantAdam}|EstherGonzalezGarcia{GonzalezGarciaEsther}|AnnaSuredaBalarí{SuredaBalaríAnna}|LydiaEccersley{EccersleyLydia}|ChengchengFu{FuChengcheng}|MeletiosDimopoulos{DimopoulosMeletios}|ClaudioCerchione{CerchioneClaudio}|AstridMcKeown{McKeownAstrid}|SumitaRoy-Ghanta{Roy-GhantaSumita}|JoannaOpalinska{OpalinskaJoanna}|JakubRadocha{RadochaJakub}|AmyPhillips-Jones{Phillips-JonesAmy}|YoshiakiKuroda{KurodaYoshiaki}|KoseiMatsue{MatsueKosei}|TakuyaKomeno{KomenoTakuya}|TakuroIshiguro{IshiguroTakuro}|JunIshikawa{IshikawaJun}|ToshiroIto{ItoToshiro}|HiroshiKosugi{KosugiHiroshi}|KazutakaSunami{SunamiKazutaka}|KazuhiroShibayama{ShibayamaKazuhiro}|HiroshiYamazaki{YamazakiHiroshi}|MitsuoInagaki{InagakiMitsuo}|YubukiNakamura{NakamuraYubuki}|YusukeIzumi{IzumiYusuke}|TadaoIshida{IshidaTadao}____Oral Session 1-19BClinical Trials in Multiple Myeloma 2____DREAMM-8: belantamab mafodotin plus pomalidomide and dexamethasone (BPd) in high-risk patients (pts)|Ophthalmic examination findings (OEFs) in patients (pts) treated with belantamab mafodotin (belamaf)|DREAMM-7: Efficacy of belantamab mafodotin + bortezomib + dexamethasone (BVd) by subsequent therapy|DREAMM-7: Belantamab mafodotin plus bortezomib and dexamethasone (BVd) in high-risk patients (pts)|DREAMM-8: updated results of belantamab mafodotin plus pomalidomide and dexamethasone (BPd)|Updated phase 2 results: teclistamab in Japanese patients with relapsed/refractory multiple myeloma

O1-19B

Oral Session 1-19B
Clinical Trials in Multiple Myeloma 2

Chair：Shigeki Ito

KoheiOkada{OkadaKohei}|MichihideTokuhira{TokuhiraMichihide}|MahoKawakami{KawakamiMaho}|KenshiSuzuki{SuzukiKenshi}|KazuhitoSuzuki{SuzukiKazuhito}|KosukeMiki{MikiKosuke}____DaisukeOgiya{OgiyaDaisuke}____KosukeMiki{MikiKosuke}|TsuyoshiSato{SatoTsuyoshi}|TatsuoOyake{OyakeTatsuo}|KazunoriMurai{MuraiKazunori}|TakutoTachita{TachitaTakuto}|HajimeSenjo{SenjoHajime}|KentaroWakasa{WakasaKentaro}|YoshihitoHaseyama{HaseyamaYoshihito}|YukariTakeda{TakedaYukari}|ToshimichiIshihara{IshiharaToshimichi}|TomoyukiSaga{SagaTomoyuki}|TomoyaHarada{HaradaTomoya}|MasahiroChiba{ChibaMasahiro}|MutsumiTakahata{TakahataMutsumi}|MasayoYamamoto{YamamotoMasayo}|KazuyaSato{SatoKazuya}|TetsuyukiIgarashi{IgarashiTetsuyuki}|KatsuyaFujimoto{FujimotoKatsuya}|SatoshiYamamoto{YamamotoSatoshi}|HidekiGoto{GotoHideki}|ShigekiIto{ItoShigeki}|TakanoriTeshima{TeshimaTakanori}|KohIzumiyama{IzumiyamaKoh}|HitomiNakayama{NakayamaHitomi}|KohtaroToyama{ToyamaKohtaro}|MotokiTakano{TakanoMotoki}|NoriyoshiIriyama{IriyamaNoriyoshi}|AtsushiTakahata{TakahataAtsushi}|ErikoSato{SatoEriko}|YasutakaSenpuku{SenpukuYasutaka}|MahoKawakami{KawakamiMaho}|KeigoOkada{OkadaKeigo}|KeisukeTanaka{TanakaKeisuke}|TakashiAbe{AbeTakashi}|YukiOsada{OsadaYuki}|KohYamamoto{YamamotoKoh}|JunichiWatanabe{WatanabeJunichi}|ToshiakiHayashi{HayashiToshiaki}|YasunobuSekiguchi{SekiguchiYasunobu}|YutaKimura{KimuraYuta}|GakuOshikawa{OshikawaGaku}|MasaruNakagawa{NakagawaMasaru}|KenSuzuki{SuzukiKen}|TakashiKumagai{KumagaiTakashi}|ShigeoToyota{ToyotaShigeo}|KatsuhiroMiura{MiuraKatsuhiro}|TakayukiIkezoe{IkezoeTakayuki}|TomonoriNakazato{NakazatoTomonori}|TakehikoMori{MoriTakehiko}|YasuhikoSenpuku{SenpukuYasuhiko}|AkiraYamamoto{YamamotoAkira}|MichihideTokuhira{TokuhiraMichihide}|AnthonyGreenwood{GreenwoodAnthony}|RebeccaDavies{DaviesRebecca}|JamesFarrell{FarrellJames}|JackWatkins{WatkinsJack}|NaokoShiraiwa{ShiraiwaNaoko}|TadaoIshida{IshidaTadao}|TadahiroGunji{GunjiTadahiro}|HidekiUryu{UryuHideki}|RikuNagao{NagaoRiku}|KenseiWatanabe{WatanabeKensei}|HirofumiYamauchi{YamauchiHirofumi}|HirokiYokoyama{YokoyamaHiroki}|AtsushiKatsube{KatsubeAtsushi}|HirotoIshii{IshiiHiroto}|AyaNakano{NakanoAya}|DaikiHattori{HattoriDaiki}|YasutakaMochizuki{MochizukiYasutaka}|YuiShiozawa{ShiozawaYui}|KeiHirano{HiranoKei}|TakashiNakamura{NakamuraTakashi}|KeitaIshii{IshiiKeita}|RyokoFukushima{FukushimaRyoko}|SusumuTanoue{TanoueSusumu}|RikaHosoba{HosobaRika}|MitsujiKatori{KatoriMitsuji}|TakeshiSaito{SaitoTakeshi}|KaichiNishiwaki{NishiwakiKaichi}|ShingoYano{YanoShingo}|KoheiOkada{OkadaKohei}____Oral Session 1-19CBiomarkers and Prognostic Factors in Multiple Myeloma and Related Disease____Prognostic impact of R2-ISS in multiple myeloma patients undergoing ASCT: A NJHSG-MM-WG Study|Investigation of early death in newly diagnosed multiple myeloma based on J-CHAEGE-MM database|Prognostic impact of chromosomal aberrations determined by FISH at diagnosis in multiple myeloma|Treatment goals and expectations of patients with relapsed/refractory MM: insights from Japan|Geriatric Nutritional Risk Index (GNRI) and ASCT predicted long survival time in myeloma|Multiple myeloma with 1% or more circulating plasma cells in peripheral blood has a poor prognosis

O1-19C

Oral Session 1-19C
Biomarkers and Prognostic Factors in Multiple Myeloma and Related Disease

Chair：Daisuke Ogiya

KazukiTanimoto{TanimotoKazuki}|KenshiSuzuki{SuzukiKenshi}|HironoIriuchishima{IriuchishimaHirono}|YuichiHorigome{HorigomeYuichi}|KentaroSerizawa{SerizawaKentaro}____KazutakaSunami{SunamiKazutaka}____YoshikaneKikushige{KikushigeYoshikane}|KentaroSerizawa{SerizawaKentaro}|KojiNagafuji{NagafujiKoji}|HiroshiHanda{HandaHiroshi}|ChikamasaYoshida{YoshidaChikamasa}|TomoakiFujisaki{FujisakiTomoaki}|TetsuyaEto{EtoTetsuya}|TakayukiIkezoe{IkezoeTakayuki}|TatsuoIchinohe{IchinoheTatsuo}|KenTakase{TakaseKen}|RyosukeOgawa{OgawaRyosuke}|JunTakizawa{TakizawaJun}|SenjiKasahara{KasaharaSenji}|TomohikoKamimura{KamimuraTomohiko}|ToshihiroMiyamoto{MiyamotoToshihiro}|TakahiroMaeda{MaedaTakahiro}|MineHarada{HaradaMine}|KoichiAkashi{AkashiKoichi}|HiroshiKosugi{KosugiHiroshi}|ToshiroIto{ItoToshiro}|YasushiTakamatsu{TakamatsuYasushi}|PeterM.Voorhees{VoorheesPeterM.}|S.VincentRajkumar{RajkumarS.Vincent}|MikuIto{ItoMiku}|ChikaSakai{SakaiChika}|MarimoTakahashi{TakahashiMarimo}|TomohikoNakatogawa{NakatogawaTomohiko}|RobynDennis{DennisRobyn}|RobinCarson{CarsonRobin}|MeletiosA.Dimopoulos{DimopoulosMeletiosA.}|MorioMatsumoto{MatsumotoMorio}|HiroyukiTakamatsu{TakamatsuHiroyuki}|TadakazuKondo{KondoTadakazu}|ThierryFacon{FaconThierry}|SonjaZweegman{ZweegmanSonja}|SatoshiKanai{KanaiSatoshi}|MelissaRowe{RoweMelissa}|SaadZ.Usmani{UsmaniSaadZ.}|AkioSaito{SaitoAkio}|MasahiroMihara{MiharaMasahiro}|ShuheiKanaya{KanayaShuhei}|RyoYoshizawa{YoshizawaRyo}|AtsushiIsoda{IsodaAtsushi}|TakuroYanagida{YanagidaTakuro}|HiroakiKonishi{KonishiHiroaki}|KoichiEhata{EhataKoichi}|NoriyukiTadera{TaderaNoriyuki}|KeiHayama{HayamaKei}|HirotoshiKamata{KamataHirotoshi}|TakahiroSuzuki{SuzukiTakahiro}|MasaakiHotta{HottaMasaaki}|ShinyaFujita{FujitaShinya}|YujiShimura{ShimuraYuji}|TadahikoMatsumoto{MatsumotoTadahiko}|JunyaKanda{KandaJunya}|SatoshiYoshihara{YoshiharaSatoshi}|Shin-ichiFuchida{FuchidaShin-ichi}|EriKawata{KawataEri}|HitoshiHanamoto{HanamotoHitoshi}|MichikoIchii{IchiiMichiko}|KentaroFukushima{FukushimaKentaro}|YosukeNakaya{NakayaYosuke}|TeruhitoTakakuwa{TakakuwaTeruhito}|TomokiIto{ItoTomoki}|JunyaKuroda{KurodaJunya}|AkifumiTakaori-Kondo{Takaori-KondoAkifumi}|ChihiroShimazaki{ShimazakiChihiro}|MasayukiHino{HinoMasayuki}|ItaruMatsumura{MatsumuraItaru}|NaokiHosen{HosenNaoki}____Oral Session 1-19DTriple and Quadruplet Therapy in Multiple Myeloma____Response-adapted consolidation post-DRd and ASCT in NDMM: interim results of the JSCT MM20 Study|Japanese subgroup analysis of the AQUILA study of daratumumab or active monitoring for high-risk SMM|Japanese subgroup analysis of the CEPHEUS study of D-VRd vs. VRd in TIE or transplant-deferred NDMM|Efficacy and safety of anti-CD38 antibody-containing triplet regimens in frail MM patients|MRD negativity in transplant-ineligible NDMM patients treated with DRd therapy in clinical practice|Real-world efficacy of isatuximab, carfilzomib, and dexamethasone in RRMM: KMF database analysis

O1-19D

Oral Session 1-19D
Triple and Quadruplet Therapy in Multiple Myeloma

Chair：Kazutaka Sunami

DaigoHashimoto{HashimotoDaigo}____ToshihiroMiyamoto{MiyamotoToshihiro}________Luncheon Seminar 1-2Pathophysiology and Treatment of Chronic GVHD____－

LS1-2

Luncheon Seminar 1-2
Pathophysiology and Treatment of Chronic GVHD

【Sponsored by Meiji Seika Pharma Co., Ltd.】

AjaiChari{ChariAjai}____ShinsukeIida{IidaShinsuke}________Luncheon Seminar 1-3Treatment strategy and safety management of Talquetamab in Triple-Class Exposed multiple myeloma.____－

LS1-3

Luncheon Seminar 1-3
Treatment strategy and safety management of Talquetamab in Triple-Class Exposed multiple myeloma.

【Sponsored by Johnson & Johnson】

HirokazuKanegane{KaneganeHirokazu}____MasafumiOnodera{OnoderaMasafumi}________Luncheon Seminar 1-4Underlying Congenital Immunodeficiencies in Hematologic Diseases____－

LS1-4

Luncheon Seminar 1-4
Underlying Congenital Immunodeficiencies in Hematologic Diseases

【Sponsored by Pharming Group N.V.】

LorenzoFalchi{FalchiLorenzo}____DaiMaruyama{MaruyamaDai}________Luncheon Seminar 1-9Bispecific antibodies in the treatment of relapsed or refractory follicular lymphoma____－

LS1-9

Luncheon Seminar 1-9
Bispecific antibodies in the treatment of relapsed or refractory follicular lymphoma

【Sponsored by CHUGAI PHARMACEUTICAL CO.,LTD.】

KazutakaSunami{SunamiKazutaka}|TadaoIshida{IshidaTadao}____Shin-ichiFuchida{FuchidaShin-ichi}________Luncheon Seminar 1-10____Erlanatamab for Relapsed and Refractory Multiple Myeloma|Treatment strategy for TCE -Based on experience with Elranatamab-

LS1-10

Luncheon Seminar 1-10

【Sponsored by Pfizer Japan Inc.】

TomokiIto{ItoTomoki}____YoshiakiTomiyama{TomiyamaYoshiaki}________Luncheon Seminar 1-11Reconstructing ITP treatment strategies from an immunological perspective ─ an approach based on TPO-receptor agonists____－

LS1-11

Luncheon Seminar 1-11
Reconstructing ITP treatment strategies from an immunological perspective ─ an approach based on TPO-receptor agonists

【Sponsored by Sobi Japan】

KouheiTsumoto{TsumotoKouhei}____YoukoSuehiro{SuehiroYouko}________Luncheon Seminar 1-12Antibody Engineering for Targeted Therapy____－

LS1-12

Luncheon Seminar 1-12
Antibody Engineering for Targeted Therapy

【Sponsored by Mitsubishi Tanabe Pharma Corporation】

KeijiNogami{NogamiKeiji}____TerutoHashiguchi{HashiguchiTeruto}________Luncheon Seminar 1-13From Bench to Bedside: The Emergence and Future Perspectives of Anti-TFPI Rebalancing Therapy____－

LS1-13

Luncheon Seminar 1-13
From Bench to Bedside: The Emergence and Future Perspectives of Anti-TFPI Rebalancing Therapy

【Sponsored by Novo Nordisk Pharma Ltd.】

HidehiroItogawa{ItogawaHidehiro}____MineoKurokawa{KurokawaMineo}________Luncheon Seminar 1-14Novel diagnostic and therapeutic approaches for disease with eosinophilia____－

LS1-14

Luncheon Seminar 1-14
Novel diagnostic and therapeutic approaches for disease with eosinophilia

【Sponsored by Incyte Biosciences Japan G.K.】

KazuakiFukushima{FukushimaKazuaki}|HidekiAraoka{AraokaHideki}____NorikoFukuhara{FukuharaNoriko}________Luncheon Seminar 1-15COVID-19, Treatment Strategies for Resistant Gram-Negative Bacterial Infections Update____Persistent SARS-CoV-2 infection in Patients with Hematologic Malignancies: Clinical Challenges and Updated Therapeutic Strategies|Antimicrobial-resistant Gram-negative infections in patients with hematological disorders

LS1-15

Luncheon Seminar 1-15
COVID-19, Treatment Strategies for Resistant Gram-Negative Bacterial Infections Update

【Sponsored by Shionogi＆Co.,Ltd.】

HirotoshiKamata{KamataHirotoshi}____TsuyoshiMuta{MutaTsuyoshi}________Luncheon Seminar 1-16Current Evidence and Emerging Therapies in Relapsed/Refractory PTCL: Present Status and Novel Treatment Options____－

LS1-16

Luncheon Seminar 1-16
Current Evidence and Emerging Therapies in Relapsed/Refractory PTCL: Present Status and Novel Treatment Options

【Sponsored by DAIICHI SANKYO COMPANY, LIMITED.】

KanaMiyazaki{MiyazakiKana}____HirokazuNagai{NagaiHirokazu}________Luncheon Seminar 1-17Optimization of Therapeutic Strategies with Acalabrutinib____－

LS1-17

Luncheon Seminar 1-17
Optimization of Therapeutic Strategies with Acalabrutinib

【Sponsored by AstraZeneca K.K.】

KeichiroMihara{MiharaKeichiro}|TakashiIkeda{IkedaTakashi}____ChihiroShimazaki{ShimazakiChihiro}________Luncheon Seminar 1-18How to use the Sarclisa® -From basic and clinical standpoints-____－

LS1-18

Luncheon Seminar 1-18
How to use the Sarclisa^® -From basic and clinical standpoints-

【Sponsored by Sanofi K.K.】

KazuhitoSuzuki{SuzukiKazuhito}____YoichiImai{ImaiYoichi}________Luncheon Seminar 1-19A New Option for BCMA-Targeted Therapeutics ～Belantamab Mafodotin as a Second-line Treatment～____－

LS1-19

Luncheon Seminar 1-19
A New Option for BCMA-Targeted Therapeutics ～Belantamab Mafodotin as a Second-line Treatment～

【Sponsored by GlaxoSmithKline K.K.】

CatherineSmith{SmithCatherine}____YasushiMiyazaki{MiyazakiYasushi}________Evening Seminar 1-2Clinical Use of FLT3 Inhibitors in AML Across the Disease Span____－

ES1-2

Evening Seminar 1-2
Clinical Use of FLT3 Inhibitors in AML Across the Disease Span

【Sponsored by Daiichi Sankyo Medical Affairs】

TakafumiTsushima{TsushimaTakafumi}|KazuyaSakai{SakaiKazuya}____AkiyoshiTakami{TakamiAkiyoshi}________Evening Seminar 1-3____Successful treatment of rapid use of Caplacizumab for TTP in clinical practice|Treatment strategies for TTP focusing on organ protection

ES1-3

Evening Seminar 1-3

【Sponsored by Sanofi K.K.】

KoheiHosokawa{HosokawaKohei}|SatoshiYamamoto{YamamotoSatoshi}____YasutakaUeda{UedaYasutaka}________Evening Seminar 1-4PNH Treatment: Up to Date____New Perspectives in the Management of PNH: A Comprehensive Understanding Including Bone Marrow Failure-Type PNH|Clinical experience with pegcetacoplan considering comorbidities

ES1-4

Evening Seminar 1-4
PNH Treatment: Up to Date

【Sponsored by Asahi Kasei Pharma Corporation】

NaokoHosono{HosonoNaoko}____KoichiAkashi{AkashiKoichi}________Evening Seminar 1-9High-Risk AML Treatment with CPX-351: Hope for Cure and Challenges in Patient Selection & Management____－

ES1-9

Evening Seminar 1-9
High-Risk AML Treatment with CPX-351: Hope for Cure and Challenges in Patient Selection & Management

【Sponsored by Nippon Shinyaku Co., Ltd.】

HiroshiUreshino{UreshinoHiroshi}____ChiakiNakaseko{NakasekoChiaki}________Evening Seminar 1-10Treatment strategy for CML in 2025 through looking back on the Bosulif 10 years____－

ES1-10

Evening Seminar 1-10
Treatment strategy for CML in 2025 through looking back on the Bosulif 10 years

【Sponsored by Pfizer Japan Inc.】

MasatoBingo{BingoMasato}____YoshiyukiOgawa{OgawaYoshiyuki}________Evening Seminar 1-11Tackling Acquired Hemophilia A: Hemostasis-Thrombosis Balance and Emerging Therapeutic Options____－

ES1-11

Evening Seminar 1-11
Tackling Acquired Hemophilia A: Hemostasis-Thrombosis Balance and Emerging Therapeutic Options

【Sponsored by Takeda Pharmaceutical Company Limited】

TomohiroAoki{AokiTomohiro}____AkihiroTomita{TomitaAkihiro}________Evening Seminar 1-12Molecular Biological Approaches to Unraveling Malignant Lymphoma: Pathogenesis and Treatment Strategies____－

ES1-12

Evening Seminar 1-12
Molecular Biological Approaches to Unraveling Malignant Lymphoma: Pathogenesis and Treatment Strategies

【Sponsored by CHUGAI PHARMACEUTICAL CO.,LTD.】

LisaMachado{MachadoLisa}|EriMatsuki{MatsukiEri}____ChikashiYoshida{YoshidaChikashi}________Evening Seminar 1-13The Next Step in CML Treatment: Integrating QoL into Clinical Decision-Making -Insights from a Global Patient Advocate and CML Expert-____Understanding QoL for patients living with CML and why it matters|Considerations on the importance of tolerability and shared decision making in the continued treatment of CML

ES1-13

Evening Seminar 1-13
The Next Step in CML Treatment: Integrating QoL into Clinical Decision-Making -Insights from a Global Patient Advocate and CML Expert-

【Sponsored by Novartis Pharma K.K.】

KoheiOkada{OkadaKohei}____KojiIzutsu{IzutsuKoji}________Evening Seminar 1-14Treatment Strategies for Waldenström's Macroglobulinemia/Lymphoplasmacytic Lymphoma (WM/LPL): Considerations for Optimal Therapy Based on Real-World Clinical Practice____－

ES1-14

Evening Seminar 1-14
Treatment Strategies for Waldenström's Macroglobulinemia/Lymphoplasmacytic Lymphoma (WM/LPL): Considerations for Optimal Therapy Based on Real-World Clinical Practice

【Sponsored by ONO PHARMACEUTICAL CO., LTD.】

YasuoMori{MoriYasuo}____ShuichiTaniguchi{TaniguchiShuichi}________Evening Seminar 1-15Management of invasive fungal infection among patients with hematologic disorders.____－

ES1-15

Evening Seminar 1-15
Management of invasive fungal infection among patients with hematologic disorders.

【Sponsored by Sumitomo Pharma Co.,Ltd.】

ShinichiMakita{MakitaShinichi}____MotokoYamaguchi{YamaguchiMotoko}________Evening Seminar 1-16Latest treatments for T/NK cell lymphoma____－

ES1-16

Evening Seminar 1-16
Latest treatments for T/NK cell lymphoma

【Sponsored by CHUGAI PHARMACEUTICAL CO.,LTD.】

KoheiTsumoto{TsumotoKohei}|ShigekiIto{ItoShigeki}____KenshiSuzuki{SuzukiKenshi}________Evening Seminar 1-17Deepening Understanding of Talquetamab from Basic Research and an Approach to the Management of Relapsed and Refractory Multiple Myeloma____The Structure and Mode of Action of Talquetamab in light of the Trends in Bispecific Antibody Development|A New Option for the Management of Relapsed and Refractory Multiple Myeloma: The Significance of Talquetamab Therapy

ES1-17

Evening Seminar 1-17
Deepening Understanding of Talquetamab from Basic Research and an Approach to the Management of Relapsed and Refractory Multiple Myeloma

【Sponsored by Medical Affairs Division, Johnson & Johnson】

DaisukeKaji{KajiDaisuke}|KotaroMiyao{MiyaoKotaro}____JunAndo{AndoJun}________Evening Seminar 1-18Frontline Approaches in the Treatment of Relapsed/Refractory Follicular Lymphoma____Recent advances in treatment for follicular lymphoma -Potential of CAR-T cell therapy-|Second-Line Therapy for Follicular Lymphoma: Exploring the Role of CAR-T and Beyond

ES1-18

Evening Seminar 1-18
Frontline Approaches in the Treatment of Relapsed/Refractory Follicular Lymphoma

【Sponsored by Bristol Myers Squibb K.K.】

YukaSugimoto{SugimotoYuka}____AkihikoGoto{GotoAkihiko}________Evening Seminar 1-19New treatment strategies for myelofibrosis____－

ES1-19

Evening Seminar 1-19
New treatment strategies for myelofibrosis

【Sponsored by GlaxoSmithKline K.K.】

AlexShih-MinHuang{HuangAlexShih-Min}____MamikoSakata-Yanagimoto{Sakata-YanagimotoMamiko}________Industry Session1-2Next-Gen Oncology: The Promise of iPSC-Derived Allogeneic Cell Therapy____Accelerating Innovation to Deliver Truly Accessible, Affordable, and Effective Allogeneic Cell Therapy

IS1-2

Industry Session1-2
Next-Gen Oncology: The Promise of iPSC-Derived Allogeneic Cell Therapy

【Sponsored by BeOne Medicines Japan】

－____－________Opening/Award Ceremony____－

NO01

Opening/Award Ceremony

－____－________JSH Business Meeting____－

NO02

JSH Business Meeting